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Abstract 
RNA Binding Motif domain protein 5 (RBM5) has been described as a lung cancer tumour 
suppressor gene.  It influences the cell cycle, apoptosis, and the alternative splicing of various 
genes.  In this study, the function of RBM5 was examined in a small cell lung cancer cell line, 
GLC20, in which RBM5 is deleted. GLC20 sublines expressing RBM5 were used for this study.  
It was observed that increased RBM5 expression associated with an increase in GLC20 cell 
death in the presence of cisplatin and a decrease in GLC20 cell proliferation.  Increased RBM5 
expression also resulted in a decrease in the EC50 of GLC20 cells towards cisplatin.  The type of 
cell death triggered by both RBM5 expression and cisplatin treatment was observed to be 
apoptosis.  Increased RBM5 expression resulted in changes in RBM10 alternative splicing. 
These results suggest that RBM5 expression may be important in the development of small cell 
lung cancer. 
 
Keywords 
RBM5, small cell lung cancer, cisplatin, GLC20, apoptosis, proliferation, cell death, RBM10, 
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Chapter 1  
1 Introduction 
1.1 RBM5 
The RNA Binding Motif protein 5 gene, otherwise known as RBM5, codes for an RNA binding 
protein and is located on the short arm of chromosome 3 
1,2
.  RBM5 was first cloned and 
identified as LUCA-15 (Lung Cancer gene 15) in 1996, and it was found within a region that is 
commonly deleted in lung cancers, 3p21.3 
1,3
.  Since 1996, it was cloned three others times: as 
H37 
4
 and RBM5 
5
 in 1999, and as LUCA15 in 2000 
6
. 
The RBM5 gene is comprised of approximately 30,000 base pairs that are transcribed into an 
mRNA transcript that is approximately 3,000 bases long.  This transcript contains 25 exons and 
possesses an open reading frame that codes for a protein of 815 amino acids 
2
 (Figure 1).  Three 
alternative-spliced variants of RBM5 have been identified. A frameshift caused by the exclusion 
of exon 6, resulting in a premature stop codon, gives rise to a transcript named RBM5Δexon6 7.  
Secondly, the addition of introns 5 and 6 results in a premature stop codon in intron 5, resulting 
in a transcript named RBM5+5+6
 6,8
. Lastly the inclusion of intron 6 results in a premature stop 
codon within the mRNA, and yields a transcript named RBM5+6 
5,6,8,9
.  RBM5 also has an anti-
sense product referred to as LUST. LUST (Luca 15 Specific Transcript) spans (exons included) a 
1.4 kb region ranging from intron 6 to intron 4 of the RBM5 gene 
10
.  This study focuses solely 
on full-length RBM5 and its function. 
The RBM5 protein has a predicted size of 90 kDa 
5
.  This was confirmed in vitro, in 1999, 
through the incorporation of 
35
S-methionine through a transcription/translation system 
4
.  On 
electrophoresis gels, RBM5 isolated from cells has a molecular weight of between 100-120 kDa  
 2 
 
 
Figure 1. Schematic representation of the exons of RBM5 and RBM10v1/v2. Reported 
transcripts for both (A) RBM5 and (B) RBM10v1/v2.  Exons are represented by grey boxes 
outlined in black.  Box sizes are not representative of actual exon size. Black ovals represent 
approximate location of the epitopes recognized by the antibodies used in this study.  Black lines 
with arrows represent the approximate location of RBM5 primers used in this study.  Solid black 
lines represent the approximate location of shRNA RBM10 targets, which were not variant 
specific. Corresponding names of antibodies, primers and shRNA are listed next to their 
approximate location. Figure was adapted from ref #29. 
 
8,11
.  The RBM5 protein has been shown to be reversibly phosphorylated, possibly indicating a 
method by which RBM5 function is regulated (to be discussed later) 
12
. 
RBM5 shows amino acid sequence homology with two other functionally related proteins, 
RBM6 and RBM10 Variants 1 and 2 (RBM10v1 and RBM10v2, respectively).  RBM6, also 
located within the 3p21.3 region, shares ~30% sequence homology with RBM5 
2,5
.  RBM10, 
located on the X chromosome at Xp11.23 
13
, shares sequence homology with RBM5 with 
RBM10v1 (49%) and RBM10v2 (53%) 
2
. These values increase to 60% and 64%, respectively, 
when exons 4, 9 and 16 are removed 
2
. This shared sequence similarity is thought to be a 
mechanism of regulation of RBM5 
14
 and may demonstrate the importance of RBM5 expression. 
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1.1.1 Expression 
Full length RBM5 is ubiquitously expressed throughout all primary tissue and non-tumour cell 
lines in humans.  RBM5 is most highly expressed in heart and skeletal muscle tissue and in the 
pancreas, as detected by Northern blot analysis 
8,9,15,16
.  RBM5 was also shown to be expressed at 
low levels in the liver 
9,15
. Most RBM5 expression studies have been performed in tumour cell 
lines and tissues. In 2002, it was shown that RBM5 was downregulated 82% at the mRNA level 
and 73% at the protein level in primary non-small cell lung cancer (NSCLC) tissue when 
compared to normal tissue 
16
.  These findings have been confirmed in two additional studies 
17,18
.  
In addition, it has been shown that RBM5 is downregulated in HRAS(G12V) transformed Rat-1 
cells 
6
.  Other reports have noted that there is also a decrease in RBM5 expression in vestibular 
schwannomas 
19
, cancerous prostatic tissue 
20
, biliary tract cancers 
21
, pancreatic ductal 
adenocarcinoma 
22
, and stage III ovarian carcinomas 
23
, compared to normal tissue.  RBM5 
expression decreases in a cisplatin-resistant A549 lung adenocarcinoma cell line relative to a 
non-resistant A549 cell line 
24
.  The RBM5 gene has also been observed to be deleted in three 
small cell lung cancer (SCLC) cell lines 
15,16,25
.  In contrast RBM5 mRNA was upregulated, 
when the human epidermal growth factor receptor 2 (Her-2) was overexpressed in MCF-7 breast 
cancer cells and CaOv-3 ovarian cancer cells 
4
. In non Her-2 over-expressing breast cancer 
samples a positive correlation between Her-2 and RBM5 expression has been noted 
4,26
.  It was 
conversely reported that RBM5 mRNA was downregulated in breast cancer samples with no 
reference to Her-2 expression, suggesting RBM5 expression levels may be regulated through the 
activity of extracellular growth factors, such as Her-2 
6
.  
In other biological systems, RBM5 was found to be upregulated after both traumatic mouse brain 
and rat spinal injuries 
27,28
.  During skeletal and cardiac muscle differentiation, RBM5 protein 
 4 
 
expression decreased over time 
29
.  RBM5 expression was also found to be different between the 
adult and the fetal thymus; expression increased in the adult thymus, suggesting it may be 
developmentally regulated 
9
.  The observed changes in RBM5 expression indicate that RBM5 
levels may be highly regulated in cells and that its function is important in various biological 
systems. 
1.1.2 Regulation 
As reviewed in Sutherland et al, 2010, RBM5 regulation is poorly understood 
25
.  Interestingly, it 
appears as though RBM5 expression is highly regulated in lung cancers, as it is consistently 
downregulated 
15
. RBM5 shares similarities in structural motifs with its functional homologues 
RBM6 and RBM10v1 and v2 
2,5
.  This duplication of similar functioning genes to different parts 
of the genome (3p21.3 and Xp11.23) has been suggested to be of evolutionary importance to 
ensure proper regulation of RBM5 or RBM5-like protein expression 
5,14
.  Loss of heterozygosity 
of a common 370 kb portion of 3p21.3, which includes RBM5, was observed in over 95% of 
SCLC and over 70% of NSCLC suggesting that the reduction of RBM5 expression, and possible 
other genes located in the deleted region, leads to the development of lung cancers 
1,15,25,30,31,32
. 
Few mutations in RBM5 have been noted 
5,33
.  Promoter hypermethylation studies to date do not 
suggest that the promoter of RBM5 is methylated 
34
, however, as noted in Sutherland et al 
25
, 
more studies are needed to make this conclusion. Recently, the promoter of RBM5 was shown to 
be mutated in melanoma samples, suggesting a possible mechanism of regulation or that the 
mutations reduced promoter function 
35
. 
The size of the RBM5 protein is roughly 90 kDa 
4,5
  but it is typically detected in SDS-PAGE 
electrophoresis at between 100 kDa and 120 kDa 
11
.  RBM5 is not N-glycosylated, but has been 
shown to be reversibly phosphorylated 
12
.  This phosphorylation appears to regulate the ability of 
 5 
 
RBM5 to promote apoptosis, as it is phosphorylated in unstressed TF-1 human erythroleukemia 
cells but is dephosphorylated in serum-starved cells undergoing apoptosis 
12
.  RBM5 expression 
appears to be regulated in instances of chemotherapy drug-resistance as its expression decreases 
in cisplatin-resistant A549 cells 
24
.  RBM5 has also been observed to be downregulated by a 
RAS-activating mutation HRAS(G12V) 
6
; however, it does not appear to be regulated by EGFR, 
which is upstream of RAS 
36
.  One can note, at least in the literature that RBM5 protein 
expression and function regulation is not very well understood. 
Recently, it was shown that a functional homologue of RBM5, RBM10, might be involved in 
RBM5 expression regulation. RBM10 knockdown correlated with an increase in RBM5 protein 
expression in SHSY5Y neuroblastoma cells 
27
.  In a separate study, RBM10 protein bound to 
RBM5 pre-mRNA in HEK293 (human embryonic kidney cells), suggesting a possible 
mechanism for the regulation of the alternative splicing of RBM5 
37
.  Lastly, it appears that 
RBM5 protein expression is regulated in skeletal and cardiac muscle differentiation, as its 
expression decreases during differentiation 
29
.  In summary, RBM5 expression appears to be 
highly regulated; however to date the mechanism for its regulation is poorly understood. 
1.1.3 Function 
In the past 15 years, much research has been undertaken in order to better understand the role of 
RBM5 in different biological systems. RBM5 is one of nine genes within a 17 gene signature 
associated with metastasis that are downregulated in various human solid tumours (including 
lung) 
38
.   In addition, RBM5 may inhibit Wnt signaling, a key player in tumour cell metastasis, 
as RBM5 knockdown in A549, Calu-6, BEAS-2B, H1299, and MCF-10A cells was associated 
with an increase in β-catenin protein expression and Rac1 protein activation 39. The same study 
further established that low RBM5 expression in primary lung tumour samples from patients 
 6 
 
correlated with increased lymph node metastasis 
39
. A similar study in 2013 suggested that low 
RBM5 expression in pancreatic cancer is associated with increased lymph node metastasis 
22
. 
These studies suggest, as reviewed by Dr. Sutherland in 2010 
25
, that the downregulation of 
RBM5 protein may be a key component for progression of lung and other cancers.  
RBM5 expression correlates negatively with the expression of other cancer-related genes 
suggesting that RBM5 plays a role in various signaling pathways.  RBM5 mRNA was 
downregulated in Rat-1 rat embryonic fibroblast cells that express HRAS, a RAS mutant that is 
constitutively activated 
6
.  RAS mutations are noted in over 30% of lung cancers 
40
. RBM5 
expression negatively correlated with increases in EGFR and KRAS expression in NSCLC tissue 
samples, and increases in KRAS expression in pancreatic cancers, further suggesting that loss of 
RBM5 expression is required for cancer progression 
18,22
. Another study performed in A549 
adenocarcinoma cells demonstrated that RBM5 overexpression resulted in a decrease in EGFR 
mRNA and protein expression 
41
.  In A549 cells treated with cigarette smoke extracts, RBM5 
protein and mRNA expression decreased as Wnt and β-catenin protein expression increased 42. 
The same study demonstrated that RBM5 overexpression resulted in a decrease in Wnt and β-
catenin protein, similar to what was shown in the Oh et al paper 
39
.  These results suggest that 
RBM5 regulates the Wnt signaling pathway upstream of Wnt and β-catenin 42. RBM5 is one of 
six genes needed for expression of AHR (aryl hydrocarbon receptor), whose expression, when 
dysregulated, can be carcinogenic 
43
.  These results further suggest that RBM5 may regulate 
signaling pathways such as Wnt/β-catenin or EGFR/RAS, and loss of RBM5 is required for 
cancer progression. 
Apoptosis is a type of energy-dependent programmed cell death characterized by many different 
morphological events 
44,45
.  There are many other modes of cell death, such as necrosis and 
 7 
 
autophagy; this study focused on apoptosis as RBM5 is a known modulator of apoptosis 
46
. 
Apoptosis is defined by morphological events such as the shrinkage and blebbing of cells, 
chromatin condensation, loss of adhesion and the eventual phagocytosis by surrounding 
macrophages 
44,45,47-49
.  In addition, apoptosis can also be characterized by various biochemical 
markers including caspase activation and cleavage, poly (ADP-ribose) polymerase proteolysis, 
ATP consumption, loss of membrane asymmetry (phosphatidylserine flipping) and DNA 
fragmentation 
45,48
.  It is generally understood that apoptosis is activated through one of two 
major pathways, depending on the type of stressor
 47
. These pathways are the intrinsic or 
mitochondria-based pathway and the extrinsic or death receptor pathway. Both pathways result 
in activation of pro-apoptotic proteins, followed by the initiation of morphological changes 
47,48,50
. 
Most RBM5 research has been investigating the role of this protein in the cell cycle and in 
apoptosis. RBM5 sensitizes Jurkat human T lymphoblastoid cells to Fas ligand, TNF-α, and 
TRAIL death receptor ligand-mediated apoptosis and also sensitizes MCF-7 human breast 
adenocarcinoma cells to TNF-α mediated apoptosis 11,51. A microarray study performed on a 
human leukemic cell line, CEM-C7, found that overexpressing RBM5 resulted in a change in 
expression of 35 genes involved in cell proliferation and apoptosis 
52
.  In the same cell line, 
overexpression of RBM5 resulted in a decrease in cell growth, and G1 cell cycle arrest 
7
, which 
was also noted in A549 cells 
17,53
.   Overexpression of RBM5 also suppressed cell growth of 
human fibrosarcoma HT108 cells 
6
, A549 cells 
17,53
, RBM5 null MCF-7 cells 
16
, A9 mouse non-
malignant fibrosarcoma cells 
16
, NSCLC H1299 cells 
54
 and PC-3 prostate cancer cells 
20
. RBM5 
overexpression also suppressed lung tumour growth 
16,17
.  In contrast, RBM5 does not appear to 
 8 
 
affect the growth of all cancer cell lines as overexpression of RBM5 had no effect on Jurkat cell 
proliferation 
11
 and non-malignant HBL-100 immortalized human cells 
16
. 
RBM5 appears to modulate apoptosis through various processes.  Increased RBM5 expression in 
A549 adenocarcinoma cells resulted in reduced cell proliferation and cell cycle arrest in G1 phase 
17,53
.  In the same cells, increased RBM5 expression promoted an increase in apoptosis via 
increased cytochrome c release, increased expression of the pro-apoptotic BAX protein, 
increased cleavage of the pro-apoptotic forms of Caspases 9 and 3, while downregulating Cyclin 
A expression and phosphorylated RB 
53
. Increased chromatin condensation and DNA 
fragmentation was also observed 
53
. Another study using A549 cells confirmed these results and 
demonstrated a decrease in protein expression of the anti-apoptotic BCL-2 and an increase in 
apoptosis observed through increased PARP cleavage and increased Annexin-V binding 
17
.  The 
ability of RBM5 to reduce cell proliferation has been shown to be independent of p53, as p53 
null H1299 human NSCLC transfected with RBM5 demonstrated a loss in cell growth 
53
.  
Overexpression of RBM5 anti-sense RNAs in Jurkat cells suppressed apoptosis mediated by Fas 
ligand, TNF-α, and staurosporine, but not etoposide, while the RBM5 anti-sense RNAs 
upregulated expression of the apoptosis inhibitor BCL-2 
55
.  In cisplatin-resistant A549 cells, 
RBM5 overexpression reduced resistance to cisplatin by increasing cisplatin-induced apoptosis 
through an increase in cytosolic cytochrome c, cleaved Caspase 9 and 3 and chromatin 
condensation 
24
.  
RBM5 function has been deemed important in the nervous system. Decreased RBM5 expression 
in SHSY5Y human neuronal cells resulted in decreased caspase activation after staurosporine 
exposure 
27
.  The same study showed an increase in RBM5 protein expression following 
traumatic brain injury and hemorrhagic shock, suggesting that RBM5 is required post-injury 
27
. 
 9 
 
RBM5 knockdown in the same cell line resulted in increased expression of cellular FLICE-like 
inhibitory protein (c-FLIP), LETm1 Domain-Containing Protein 1 (LETMD1) and amyloid 
precursor-like protein 2 (APLP2) but decreased Caspase 2 
27
. In a similar study, RBM5 mRNA 
and protein expression increased following spinal cord injury along with pro-apoptotic BAX 
protein, tumour suppressor gene p53 and cleaved Caspase 3 
28
.  RBM5 knockdown in neuronal 
PC12 cells resulted in decreased p53 expression 
28
.  This result is identical to a previous study 
that demonstrated increased p53 expression when RBM5 was expressed, and decreased p53 
expression when RBM5 was knocked down in various cell lines 
54
.  RBM5 expression also 
potentiated p53 inhibition of H1299 cell growth in the same study.  These results, with the 
previous results from Oh et al 
53
, suggest that RBM5 acts upstream of p53 when suppressing cell 
growth and activating apoptosis.  Taken as a whole, RBM5 is a potent modulator of apoptosis 
and regulator of the cell cycle. 
As an RNA-binding protein, RBM5 has been implicated in the alternative splicing of pre-mRNA 
involved in cell proliferation, the regulation of apoptosis and cell signaling pathways 
56
.  RBM5 
and its functional homologue, RBM10, are components of pre-spliceosomal complexes 
57,58
.  
RBM5 binds to spliceosomal complex proteins DHX15 and PRP19, with RBM5 stimulating 
DHX15 helicase activity (a process required in splicing of pre-mRNA) 
59
.  RBM5 promotes the 
exclusion of exon 9 of Caspase 2, resulting in the expression of a proapoptotic variant of Caspase 
2 
60
.  Retention of exon 9 results in a Caspase 2 isoform that does not induce apoptosis.  RBM5 
also promotes the exclusion of exon 6 of Fas receptor, resulting in a form of Fas that does not 
promote apoptosis 
61
.  In the same study, RBM5 influenced the exclusion of exon 7 of c-FLIP, 
leading to a variant that regulates apoptosis 
61,62
.   Interestingly, an anti-sense sequence of Fas 
has the ability to bind RBM5 and regulate the alternative splicing of Fas at exon 6 
63
.  These 
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findings suggest a role for RBM5 in promoting the alternative splicing regulation of key proteins 
involved in apoptosis regulation.  Recently, the two RRM domains in RBM5 were found to be 
required for both its alternative splicing function and its ability to modulate apoptosis and cell 
proliferation in A549 cells 
64
.  Overall, it appears as though the ability of RBM5 to regulate 
alternative splicing may be key to its function in regulating cell cycle progression and apoptosis. 
RBM5 has also been implicated in the alternative splicing of other targets.  Increased RBM5 
expression resulted in an increase in exon 4 skipping of AID (Activation-induced cytidine 
deaminase) pre-mRNA, establishing a putative oncogenic isoform 
65
.  RBM5 enhances exon 40 
and 72 skipping of Dystrophin pre-mRNA 
66
.  Dysregulation of Dystrophin protein expression 
results in diseases such as Duchenne Muscular Dystrophy (DMD), resulting in a loss of muscle 
and possibly death 
67
.  Exon skipping has shown to restore some function of Dystrophin protein, 
resulting in a less severe disease in some cases 
68
.  Lastly, RBM5 has been implicated in mouse 
spermatid differentiation, as a single missense mutation in the second RRM domain resulted in 
spermatid differentiation arrest and apoptosis 
69
.  The missense mutation resulted in a splicing 
error in 11 spermatid differentiation specific pre-mRNAs, suggesting proper RBM5 expression is 
required for spermatid differentiation 
69
.  The role of RBM5 in spermatid differentiation and 
Dystrophin alternative splicing suggests that RBM5 may have a role in development. 
1.2 RBM10 
1.2.1 Splice variants 
RBM10 or RNA Binding Protein Motif 10, was first cloned and identified in 1995 from bone 
marrow tissue 
13
. The RBM10 gene is located on the X chromosome at Xp11.23 and has one 
allele silenced in each somatic cell through X chromosome inactivation 
70,71
.  RBM10 has three 
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identified variants termed RBM10 variant 1 (RBM10v1), RBM10 variant 2 (RBM10v2) and 
RBM10 variant 3 (RBM10v3) 
2,72,73
.  As noted in Figure 1, RBM10v1 is the full length variant 
consisting of 24 exons, while RBM10v2 lacks exon 4 and consists of 23 exons 
2,72
. RBM10v3 is 
a much smaller variant due to an alternate transcriptional start site and a 23 bp deletion in exon 4 
that results in a premature stop codon 
72
.  Both RBM10v1 and RBM10v2 have alternative 
isoforms with or without the addition of one valine residue 
74
. This study will focus on 
RBM10v1 and v2 expression and function, irrespective of the additional valine isoforms. 
The RBM10 gene is comprised by approximately 42,000 base pairs, which is transcribed into two 
mRNA variants. RBM10v1 is a 3402 base transcript which codes for a 930 amino acid protein 
2
.  
RBM10v2 is a 3171 base transcript with 23 exons that lacks the 231 base exon 4. RBM10v2 
codes for a protein 853 amino acids in size 
2,73,74
.  As mentioned previously, both RBM10v1 and 
v2 share roughly 50% protein sequence homology with RBM5 (49% and 53%, respectively) 
RBM10v1 protein is a 103 kDa protein while RBM10v2 codes for a 94.5 kDa protein.  Both 
variants have alternative isoforms that either have or do not have an additional valine located at 
amino acid 354 for RBM10v1 and 277 for RBM10v2 
74
.  The presence of the valine appears to 
inhibit the formation of one of the two α-helices located in the RRM tertiary structure 74. 
Although RBM5 and RBM10 share a high degree of homology, they do have three exons that 
differ in the amino acid sequence they encode. Exon 4 of RBM10v1 is non-existent in RBM5, 
while exons 9 and 15, which are identical in both RBM10 variants, share only 14% homology 
with RBM5 
2
.  Due to the high degree of homology, it would appear that RBM5 and RBM10 
share some similar functions. 
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1.2.2 Expression 
RBM10 is ubiquitously expressed throughout human primary tissue and cell lines 
70,71
.  RBM10 
is mutated in 7% of lung adenocarcinomas with an increased mutational incidence in males over 
females 
40,75
.  Furthermore, it has been reported that some RBM10 mutations in lung 
adenocarcinomas result in a truncated form of the protein being expressed 
75
.  RBM10 mutations 
have also been observed in pancreatic intraductal papillary mucinous neoplasms 
76
, and appear to 
correlate with longer survival times with treatment, despite leading to a more aggressive cancer 
77
.  RBM10 mutations have also been implicated in TARP syndrome (Talipes equinovarus, Atrial 
septal defect, Robin sequence, and Persistent left superior vena cava) 
73,78,37
.  TARP syndrome is 
a rare developmental abnormality that results in early death within infancy 
73,78,79
. Lastly, 
RBM10v1 protein expression decreases towards the end of rat skeletal muscle differentiation, 
while RBM10v2 mRNA and protein expression decreased in rat skeletal muscle differentiation. 
RBM10v2 protein expression also decreases in rat cardiac muscle differentiation 
29
.   
1.2.3 Function 
Before 2005, there was no data on how RBM10 functioned 
2
.  It is now understood that RBM10 
is involved in the alternative splicing of various transcripts.  Supporting this view, RBM10 has 
been purified in pre-spliceosomal complexes 
57,58
.  RBM10 was found to promote the exclusion 
of exon 18 of DLG4 (Discs Large Homolog 4 of post-synaptic density protein 95), while RBM10 
knockdown resulted in an increase in the inclusion of exon 18 
80
.  In addition, RBM10 influenced 
the alternative splicing of FasR, c-FLIP, and BCL-x, but not of Caspases 2, 3 and 9 
61,81
.  In these 
instances, RBM10 appeared to influence exon 6 exclusion of FasR, resulting in an increase in the 
soluble of FasR, an anti-apoptotic protein, whereas it also activated pro-apoptotic forms of c-
FLIP and BCL-x (S) 
81
. Furthermore, RBM10 affected the alternative splicing of exon 11 in 
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NUMB, a key NOTCH pathway regulator, amongst other genes 
56
.  The NOTCH pathway is 
involved in regulating cell proliferation 
56
. A study from the Sutherland group expanded on this 
research, demonstrating that a two-fold increase in the RBM10v1 isoform without a valine in the 
second RRM domain resulted in preferential expression of NUMB with the inclusion of exon 11, 
which is lung cancer specific 
74
.  With the role of RBM10 in alternative splicing, a model was 
produced in 2013 that describes the splicing mechanism of RBM10.  As described in this model, 
RBM10 binds preferentially to intronic sequences that surround exons, resulting in exon 
exclusion 
37
. Various nuclear localization signals in RBM10 have been reported, regulating its 
localization to the nucleus, further implicating its role in alternative splicing regulation 
82
.   
RBM10 is involved in regulating cell proliferation and apoptosis.  In primary chondrocytes 
induced to hypertrophy, an increase in RBM10 expression correlated with a decrease in cell 
proliferation and an increase in apoptosis 
83
.   In breast cancer specimens, RBM10 mRNA was 
positively correlated with Caspase 3 protein, an important apoptosis protein 
84
.  In another study 
with breast cancer specimens, RBM10v1 expression correlated with the expression of 
proapoptotic BAX and the tumour suppressor gene p53 
85
.  In the same study, both variants of 
RBM10 mRNA were positively correlated with VEGF mRNA, a promoter of new blood vessel 
growth 
85
.  In the study that demonstrated RBM10 regulation of NUMB alternative-splicing, 
RBM10 knockdown increased the proliferation of HeLa cells 
56
.  A recent study in 2015 using 
SHSY5Y human neuronal cells showed that RBM10 knockdown augmented proapoptotic 
caspase activity after staurosporine exposure 
27
.  The same study showed that RBM10 expression 
increased after hemorrhagic shock and traumatic brain injury 
27
. They also demonstrated that 
RBM10 knockdown resulted in an increase in RBM5 protein expression 
27
. In a study performed 
by the Sutherland group, a connection between RBM10 expression and TNFα (tumour necrosis 
 14 
 
factor) expression was drawn 
72
.  When RBM10 expression was knocked down, both TNFα 
mRNA and soluble TNFα protein expression decreased, resulting in decreased apoptosis 72.  
When RBM10 was overexpressed, TNFα mRNA and soluble protein expression increased, 
resulting in increased apoptosis 
72
.  Thus, RBM10 appears also to be a modulator of apoptosis. 
Lastly, RBM10 appears to play a role in the etiology of different diseases.  In patients with 
metastatic melanoma, high RBM10 expression was correlated with increased aggression of the 
disease, but patients responded positively to treatment with BRAF inhibitors 
86
. Further research 
is needed to fully understand its role in cellular processes as well as in various diseases.  
1.3 Lung cancer 
1.3.1 Incidence and prevalence 
In both Canada and worldwide, lung cancer is the leading cause of cancer-related deaths 
87,88,89
.  
In 2011, there were more than 1.5 million new cases of lung cancer and 1.3 million lung cancer 
related deaths worldwide 
88
.  Approximately 13.5% of new cases of cancer in Canada are lung 
cancer for both men and women, ranking third behind prostate and colorectal cancer for men and 
second behind breast cancer for women 
89
.  Canadian Cancer Statistics estimates that lung cancer 
is the leading cause of cancer-related deaths in Canada, with an estimated 26.6% men and 27% 
of women dying from cancer due to lung cancer. With the increase in lung cancer morbidity and 
mortality, lung cancer is a serious disease that warrants further research and understanding. 
The World Health Organization states that the leading cause of lung cancer is tobacco related 
87
. 
Approximately 85% of lung cancers are reported to be due to smoking 
90
.  Worldwide, smoking 
is the cause of 80-90% of men’s lung cancers and 50% of women’s lung cancers 87,91,92. 
Furthermore, many cases of lung cancer occur in people who have never smoked or those who 
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have ceased smoking for many years 
93,94
.  Other known causes of lung cancer include, but are 
not limited to, exposure to asbestos, arsenic, radon, and polycyclic aromatic hydrocarbons 
95
.  In 
addition, in many Asian countries, there is an increase in lung cancer incidence amongst women 
due to increased indoor air pollution from coal-fuelled stoves and cooking fumes 
96
.  Although 
the primary cause of lung cancer is tobacco smoke, further research is warranted on the 
additional factors contributing to lung cancer incidence. 
1.3.2 Subtypes 
Lung cancers can be classified into two main subtypes: NSCLC and SCLC 
87
.  NSCLC has three 
major subtypes called adenocarcinoma, squamous cell carcinoma and large cell carcinoma, 
whereas SCLC has no subtypes 
87
.  Approximately 80-90% of all lung cancers are diagnosed as 
NSCLC and approximately 10-20% of all lung cancers are diagnosed as SCLC 
87,97,98
.  
Lung cancers, like all other cancers, have many molecular aberrations compared to normal lung 
tissue, including mutational changes, gene expression changes, and chromosomal alterations 
87
.  
Table 1 highlights the major chromosomal alterations that have been documented for each lung 
cancer subtype. The most common NSCLC chromosome changes are found as deletions within 
1q, 8p, and 10q, which appear specific to NSCLC 
87
.   Common changes amongst all NSCLC 
and SCLC include deletions within chromosomes 3p, 4, 5q, and 10q, additions within 
chromosome 8q, and changes within chromosome 17 
87
.  Of particular interest are deletions 
within chromosome 3p, since these are the earliest chromosomal aberrations that may contribute 
to lung carcinogenesis. 
Table 2 provides examples of some of the major genetic alterations in the form of common 
mutation and expression changes for each subtype. As with all cancers, lung cancer has many  
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Table 1. Common chromosomal alterations found in lung cancer subtypes. 
Lung Cancer Subtype Chromosomal aberrations 
   
NSCLC Adenocarcinoma - 2q
99
, 3p
87,32
, 4q
87
, 5q
87
, 6q
 87,99
, 8p
87
, 9p
87
, 10q
99
 13q
87
, 
17q
99
, 18q
87
, 22q
87
 
+ 1q
87
, 5p
87
, 8q
87
, 20q
87 
   
 Large cell - 3p12-14
87
, 3p21
32
, 4p
87
, 5q21
87
, 8p22-23
87
, 8q
87
, 21q
87 
+ 1q21-22
87
, 3q
87
, 8q
87 
   
 Squamous - 3p21
32,87,100 
, 4q
87
, 5q
87
, 8p22
100
, 9p21-22
100
, 10q
87
, 11q
87
, 
13q
87, 100
, 17p12-13
100
, 18q
87
, 21q
87 
+ 1q31
100
, 3q25-27
100
, 5p13-14
87, 100
, 8q23-24
87, 100
, 8p12
87
, 
11q13
87
, 12p
87 
   
SCLC None - 3p (3p12-13, 3p4, 3p21, 3p24-26)
 32,87 
, 4p
87
, 5q
87
, 10q
87
, 
13q
87
, 17p
87
 
+ 3q
87
, 5p
87
, 6p
87
, 8q
87
, 17q
87
, 19
87
, 20q
87 
   
- loss of heterozygosity/homozygosity 
+ gain of chromosomal region 
 
different genetic alterations. Although there are many differences between the subtypes, there are 
also similarities and oddities.  For example, the most common genetic alteration is found in the 
tumour suppressor gene p53, which has a loss-of-function mutation in the majority of all 
subtypes of lung cancer 
40,87,101,103
.  KRAS gain-of-function mutations are common in 30% of 
adenocarcinoma and are also present in large cell carcinoma; however, these mutations occur 
infrequently in both squamous cell carcinoma and SCLC 
40,87,101,103
. Although not common in 
lung cancer, loss of PTEN function through decreased expression and/or loss-of-function 
mutations appears common in all subtypes 
87,100,103
. Most of the NSCLC subtypes share many 
mutations and expression changes in Her-2/Neu, EGFR, PI3K, and Cyclin D1 and E 
40,99,100,101
.  
SCLC, one of the major subtypes of lung cancers, appears to share very few genetic alterations 
with the other subtypes, however, there are a few genes with common alterations such as those 
that lead to upregulation of the oncogene MYC, in both SCLC and adenocarcinoma, and the 
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Table 2. Common molecular alterations found in lung cancer subtypes. 
Lung Cancer Subtype Mutations Expression Changes 
    
NSCLC Adenocarcinoma KRAS (+)
40,87
 , EGFR 
(+)
40,99
 , BRAF (+)
40,99 
, 
PI3K (+)
40
, p53 (-)
40,87,99, 
, 
RBM10 (-)
40
, RIT1 (+)
40
, 
MGA (-)
40
, P16INK4 (-)
87, 
99
, STK11(-)
40 
COX2 (+)
87
, HER2/Neu (+)
99
, 
MET (+)
40,99 
, MYC (+)
40
, 
PTEN (-)
99
, Cyclin D1 +E 
(+)
87, 99
 
    
 Large cell MEN1 (-)
87
, KRAS (+)
87
, 
p53 (-)
87 
P16INK4 (-)
87
, Cyclin D1 +E 
(+)
87,99
, Bax (-)
87
, Bcl-2 (+)
87
, 
PTEN (-)
99 
    
 Squamous PIK3CA (+)
87
, p53 (-)
87, 
99,117
, EGFR (+)
87,99
, 
Her2/Neu (+)
87,99
, PTEN (-
)
99
, PI3K (+)
99,101
, HLA-A 
(-)
101
, CDKN2A (-)
101
, 
P16INK4 (-)
101
, PIK3CA 
(+)
87
, RB1 (-)
87,101
 
SOX2 (+)
102,101
 , FGFR (+)
87, 
99,101
, PTEN (-)
114,100,117
 , 
CDKN2A (-)
101
, Cyclin D1 +E 
(+)
87,99
, EGFR (+)
101
, 
P16INK4 (-)
87,99
, FGFR1 
(+)
100,101  
    
SCLC None RB1 (-)
87,103,104
, SOX2 (+)
 
102
, p53 (-)
87,103
, PTEN (-
)
103
, RASSF1 (-)
104
, FHIT (-
)
104
, FUS1 (-)
104
  
RB1 (-)
87,103
, SOX2 (+)
 102
, 
MYC (+)
87,116,103
, E2F1 (+)
87
, 
FGFR (+)
103
, BCL-2(+)
87
 
    
- loss of function mutation/decrease in expression 
+ gain of function mutation/increase in expression 
 
overexpression of SOX2 and FGFR1, in both SCLC and squamous cell carcinoma 
40,99,100,101,102
.  
Lastly, of particular interest, RBM10 was found to be mutated in 7% of lung adenocarcinomas, 
with an increased incidence of mutation in males over females 
40,75
. 
1.4 Small cell lung cancer 
1.4.1 Characteristics 
As mentioned previously, approximately 10-20% of all lung cancers are diagnosed as small cell 
lung cancer (SCLC), a major subtype of lung cancer 
87,97,98
.  Historically, SCLC was also termed 
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oat cell carcinoma, small cell anaplastic carcinoma and intermediate cell type 
87
.  SCLC tumours 
are characterized as small white tumours that are difficult to image through radiographs (X-ray 
or CT-scan) 
87
.  Cytological specimens show SCLC cells as characterized by scant cytoplasm 
dominated nearly entirely by the nucleus. The cells form clusters/sheets or irregular linear 
patterns 
87
. Cells borders commonly blend together, making it difficult to identify individual cells 
87
.  At the time of diagnosis, SCLC has generally metastasized to other localized regions of the 
body (lymph nodes, central nervous system, brain) 
87,104
.  SCLC is considered the most 
aggressive subtype of all the lung cancer subtypes, and, in addition to metastasis, commonly 
develops resistance to chemotherapy, generally after demonstrating a good response to treatment 
87,104
.  Most patients with SCLC will relapse after the initial treatment shows a reduction of the 
disease 
104
. 
SCLC has many different chromosomal and molecular aberrations compared to the 
corresponding normal lung tissue, as noted in Table 1 and Table 2.  As mentioned previously, 
nearly 100% of all SCLCs have a chromosome 3p deletion, with over 95% of cases having at 
least loss of heterozygosity at the 3p21.3 region, containing RBM5 
15,32,87
.  Many specific 
mutations with high incidence in SCLC occur in genes mapping to chromosome 3p, including 
FHIT, RASSF1, RARB, and FUS1 
87,102,103,104
.  All four of these genes, located within the 3p14-
23 region, have demonstrated anti-tumorigenic properties relating to the cell cycle and/or 
apoptosis regulation 
104,105,106,107,108
.    Abnormalities in these four genes occur in over 70% of 
SCLC 
104
.  In addition, RB1 and p53 mutations occur in over 80% of all SCLCs 
87,103,104
, while 
PTEN is mutated in approximately 8% of SCLCs 
87,102,104
.    
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1.4.2 Staging and survival 
SCLC is classified as two different stages by the Veteran’s Administration Lung Study Group: 
limited stage (LS) and extensive stage (ES) 
87,104,109
.  Table 3 presents the two different stages, 
their associations with patient survival and staging diagnosis. LS is defined as occurring within a 
single field of radiation therapy (within one lung and localized lymph nodes) while ES is defined 
as not being within a single field of radiation therapy or as having metastasized to another 
location(s) 
104,109
. A single field of radiation therapy is the region covered by one beam of 
external radiation. Approximately 60% of patients fall within ES 
98,110
, while the remaining are 
LS 
98,104
.   
Table 3. SCLC stages and survival. 
Stages Survival  Description 
   
Limited Stage 
(LS) 
Median: ~17 months 
5-year survival: 10-17% 
Cancer is within a single field of radiation therapy  
Eg: in 1 lung, the mediastinum (lung cavity), 
and/or local lymph nodes 
   
Extensive Stage 
(ES) 
Median: ~7 months 
5-year survival: 2% 
2-year survival: 5% 
Cancer has spread outside a single field of 
radiation therapy 
Eg: other lung, brain, liver, bone, or nonlocal 
lymph nodes  
   
Note – information was pooled from references 98, 104, 109, 110, 111, and 115  
 
Survival rates for SCLC are very poor, as it is estimated that 95% of diagnosed patients will 
eventually succumb to the disease 
98,104,110
.  Survival generally depends on the extent disease 
burden, the sex of the patient, and his or her overall health 
98,104
.  LS patients, with limited spread 
of the disease, have a greater chance of survival, as 80% of cases show a complete response to 
treatment 
104
.  LS patients have a 5-year survival rate of 10-17%, with a median survival of just 
over 17 months 
98,104,111
.  ES patients show 20% complete response to treatment, with a 2-year 
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survival rate of 5%, and a 5-year survival rate of approximately 2% 
98,104,110
.  The median 
survival for ES patients is 7 months 
104,110
. Given the poor outcomes from SCLC, it appears as 
though more research is necessary to provide greater knowledge to prevent or treat the disease. 
 
1.4.3 Treatment 
SCLC is commonly treated based on the stage of the disease.  Tumour resection is uncommon in 
North America, due to the cancer having metastasized at the time of presentation 
87,104,112
.  In 
recent years, surgery has been shown to be a viable treatment option for those few patients with 
early LS SCLC 
112,113
.  Studies in the United Kingdom have shown that in early LS SCLC cases, 
surgery results in an increase in the 5-year survival of patients from 5% to 52% 
114
.  Although 
there is evidence that tumour resection can be successful, the majority of SCLC treatments are 
based on the stage of the cancer, the presence of metastatic disease, and whether or not the 
cancer has relapsed after chemotherapy and radiation therapy. 
Table 4 highlights the most common treatments for each stage of SCLC.  Treatments in the table 
are based on what can be found in the literature as well as what is performed in Canada, taken 
from the Canadian Cancer Society 
115
.  The most common chemotherapy treatment for each 
stage of SCLC is a combination of platinum-based agents, such as cisplatin or carboplatin, and 
the topoisomerase inhibitor, etoposide 
104,116
.  Cisplatin is generally chosen over carboplatin due 
to its increase effectiveness, however, carboplatin demonstrates less toxicity 
117
. In instances 
where a patient with LS disease is healthy, radiation therapy is coupled with the cisplatin and 
etoposide treatment 
104,116
. In the past, and in rare cases, a combination of cyclophosphamide, 
doxorubicin, and vincristine was used to treat LS SCLC 
104
. For ES patients, cisplatin and 
etoposide are still the preferred treatment 
104
.  In some instances, other topoisomerase inhibitors, 
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such as topotecan and irinotecan, are coupled with cisplatin 
104
, because they show a better 
response in comparison to cisplatin and etoposide 
118
.  For ES patients, radiation therapy is 
reserved for those with metastatic ES, typically for those in palliative care 
104,116
.  Lastly, as 
mentioned previously, most SCLC patients relapse sometime after the disease shows a complete 
response (defined as a complete reduction of the visual tumour via imaging) to the treatment, as 
the cancer develops a resistance to the original treatment 
104
.  In these cases, a combination of 
cyclophosphamide, doxorubicin and vincristine is used, or a topoisomerase inhibitor on its own 
104
.  Understanding how SCLC responds to and develops resistance to common treatments, such 
as cisplatin, is important in order to understanding how to maximize the efficiency of SCLC 
treatments, in order to increase SCLC survival rates. 
Table 4. Common treatments of SCLC in North America. 
Stages Common Treatment 
  
Limited stage (LS) etoposide + cisplatin/carboplatin +/- radiation therapy 
 
cyclophosphamide + doxorubicin + vincristine 
 
Extensive Stage (ES) etoposide + cisplatin/carboplatin +/- irinotecan/ topotecan 
 
etoposide + cisplatin/carboplatin + cyclophosphamide +epirubicin 
 
etoposide + cisplatin/carboplatin +/- ifosfamide 
 
radiation therapy (palliative) 
 
Recurrent disease topotecan 
 
cyclophosphamide + doxorubicin + vincristine 
 
irinotecan +/- topotecan +/- paclitaxel 
 
Note – information was pooled from references 104, 115, 116, and 118 
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1.4.3.1 Cisplatin 
Cisplatin, or cis-diamminedichloroplatinum, was first discovered to have anti-tumour capabilities 
in the late 1960’s 119.  As a result, cisplatin is now used in the treatment of a large number of 
cancers including lung, ovarian, head and neck, testicular, and gastric cancers 
120,121
.  
Unfortunately, many cancers have an intrinsic resistance to cisplatin, while others, such as 
SCLC, develop a resistance to cisplatin upon treatment 
121,122
.  It is commonly understood that 
cisplatin’s mode of action is through the formation of DNA adducts, which result in the 
activation of various pathways that lead to programmed cell death or apoptosis 
121,123
. Nucleotide 
excision repair (NER) and mismatch repair (MMR) proteins, such as HMG1, recognize the DNA 
damage, resulting in activation of p53 and MAPK pathways (amongst others), leading to first 
cell cycle suppression, initiation of repair, and if not possible to repair/restore cell cycle 
progression, the activation of apoptosis, and in some cases necrosis or S/G2 phase cell cycle 
arrest 
121,122,124,125
. In addition, cisplatin binds to cytoplasmic proteins at cysteine residues 
126
.  
This interaction also leads to p53 and MAPK apoptotic cell death, however, it may also lead cells 
to undergo necrosis 
121,122
.  It has been suggested that cells undergo cisplatin-induced necrosis if 
there are errors in the apoptotic mechanism 
122
. 
Various concentrations of cisplatin have been reported in lung cancer cell-base treatment models.  
In A549 cells, a lung adenocarcinoma cell line, the IC50 values towards cisplatin (the 
concentration of drug that inhibits the growth of 50% of the cells) has been reported to be 
anywhere from 3.1 µM 
127
 after four hours of exposure to cisplatin to 2.3 µM 
128
 to 64-70 µM 
after 48 hours of exposure to cisplatin 
129
. Furthermore, some SCLC cell lines, such as GLC20 
and DMS114, have IC50 values towards cisplatin reported as 75.0 µM after 1 hour and 1.6 µM 
after 4 hours, respectively 
127,130
.  The variance in reported IC50s, even for the same cell line, may 
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be due to differences in the preparation of the cisplatin solutions.  As early as 2008, it was shown 
that cisplatin is deactivated in dimethylsulfoxide (DMSO) 
131
 and that the proper preparation of 
cisplatin is in an aqueous saline solution 
132,133
.  Many publications do not disclose their method 
of cisplatin preparation, making it difficult to interpret results 
133
.   
1.5 GLC20 SCLC cell model 
GLC20 is a SCLC cell line first reported in 1992 from the University Hospital Groningen in the 
Netherlands 
130
.  The cells were derived from a 67-year old male SCLC patient who was treated 
with a mixture of cyclophosphamide, doxorubicin and vincristine, with no reported tumour 
regression 
130
.  The male patient eventually passed away 28 weeks after diagnosis 
130
.  The 
GLC20 cell line has a homozygous 440 kb deletion on the short arm of chromosome 3, at the 
location 3p21.3 
3
.  This cell line was instrumental in the discovery of the 3p21 deletion that is 
common in many lung cancers 
1,5,15,32
.  This deletion region overlaps with the smallest lung 
cancer specific deletion observed with two other SCLC cell lines, NCI-H740 and NCI-H1450 
1
. 
This deletion encompasses RBM5, resulting in a homozygous deletion of RBM5, providing a 
potential model to observe the effect of induced RBM5 expression 
15
 (Figure 2). 
In addition to the wild type GLC20 cells, Dr. Leslie Sutherland previously developed three 
GLC20 stable sublines, two of which express RBM5 at differing levels.  One subline contains an 
empty expression vector was termed Vector (V) or pcDNA3, while the cell lines containing 
RBM5 expression vectors were termed T2 (low-expression of RBM5) and C4 (high-expression 
of RBM5), as denoted in Figure 3.  The pcDNA3 and T2 sublines were created from pooled 
populations of transfected cells selected in G418/geneticin.  Soft agar cloning was performed to 
produce the clonal population C4, which was also selected in G418/geneticin.   
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Previously, GLC20 cells were shown to have an IC50 for cisplatin of roughly 75.0 μM after one 
hour of exposure to cisplatin 
130
 and a reduction in cell growth with 0.4 µM cisplatin after four 
days of exposure 
134
.  Very few experiments have been performed with the GLC20 cells, 
however the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) enzymatic 
activity assay has been used on a few occasions to measure drug sensitivity 
130
. In Dr. 
Sutherland’s laboratory, wild type GLC20 cells are most commonly used as a negative control  
 
Figure 2. The location of RBM5 on chromosome 3 and deletion in GLC20 cells. (A) A 
schematic representation of the location of RBM5 on the small arm of chromosome 3, at 3p21.3. 
(B) The deletion region of the 3p21 deletions in 3 different SCLC cell lines.  Lines presented are 
the end-point of deletions that encompass RBM5.  Figure was obtained and edited from Dr. 
Sutherland, from a manuscript under preparation. 
 
for RBM5 variant transcription analysis 
10,135
.  GLC20 cells have also been used to study RBM10 
variants with two isoforms with or without a valine located in the second RRM domain 
74
.  
GLC20 cells contain twice as much of the RBM10v1 valine-lacking isoform compared to the 
valine-containing isoform, meaning there is more exon 11-expressing than exon 11-excluding 
NUMB protein 
74
.  The exon 11 expressing NUMB variant is associated with lung cancer 
56
. 
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Figure 3. RBM5 expression in established GLC20 sublines. RBM5 (A) RNA and (B) protein 
expression analysis of previously established GLC20 sublines.  ‘V’ is representative of the 
pcDNA3-transfected subline.  Figure was obtained from Dr. Sutherland, from a manuscript 
under preparation. 
 
1.6 Study Objectives 
To date there has been a growing understanding of the expression and mutation status of RBM5 
in lung cancer 
15,16,34
. Its location within the region 3p21.3 that suffers allelic loss in over 95% of 
SCLC and over 70% of NSCLC, suggests a function as a lung cancer tumour suppressor gene 
1,30,31,32
.  There are many studies that have attempted to understand the role of RBM5 in many 
different cell models, including its role as a tumour suppressor gene in NSCLC models.  As a 
result, the main objective of this study was to further examine the function of RBM5 in lung 
cancer, using the GLC20 SCLC model.  As described earlier, wild type GLC20 cells are RBM5-
null. Using the two RBM5-expressing GLC20 sublines previously described, T2 and C4 (Figure 
3), this study aimed to understand of the function of RBM5 by comparing various phenotypes in 
the RBM5-null and RBM5-expressing cell model. Specifically, our objective was to observe the 
effect of RBM5 expression on GLC20 cell proliferation, cell death and apoptosis.  Our first aim 
was to monitor the effect of RBM5 expression on GCL20 cell proliferation using both the MTT 
and cell counting assays.  Second, we observed the effect of RBM5 expression on GLC20 cell 
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death in the presence of cisplatin using the cell counting assay.  Third, we examined cells 
undergoing cell death by observing changes in PARP cleavage by Western blotting, and 
chromatin condensation and membrane asymmetry by fluorescence microscopy, to determine the 
influence of RBM5 expression on apoptosis.  With the understanding of the ability of RBM5 to 
modulate apoptosis and the cell cycle 
46
, we hypothesized that increased RBM5 expression 
would result in a decreased GLC20 cell proliferation and, in the presence of cisplatin, increases 
in apoptotic cell death.  We also hypothesized that the effect of RBM5 would depend on its 
expression level.   
During the course of our investigation we also noted that increased RBM5 expression was 
associated with a change in RBM10v1/v2 expression.  Therefore, this study explored the 
function of RBM10 in the GLC20 cell model.  Since RBM10 is a modulator of apoptosis and a 
regulator of cell proliferation 
56,72
, we hypothesized that RBM10 knockdown would result in an 
increase in GLC20 cell proliferation.  GLC20 RBM10 knockdown sublines were produced from 
pooled populations using shRNA-targeting RBM10.  The effect of RBM10 knockdown on cell 
proliferation was explored, using an MTT assay.   
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Chapter 2  
2 Materials and Methods 
2.1 GLC20 cells and sublines 
SCLC GLC20 cells were a kind gift from the late Dr. Charles Buys from the University of 
Groningen (Groningen, Netherlands) and Dr. Leslie Sutherland previously generated the GLC20 
RBM5-expressing sublines.  GLC20 cells and sublines pcDNA3, T2 and C4 were maintained in 
RPMI 1640 (Gibco, Life Technologies, Burlington, Canada) supplemented with 10% fetal 
bovine serum (FBS, Gibco) (termed complete medium), with the addition of 0.1 mg/mL 
G418/Geneticin (Gibco)  for pcDNA3, T2 and C4 sublines.  Cells were maintained at 37°C with 
5% CO2 in a humidified chamber. Cells were scaled up and collected by centrifugation at 149 x g 
for 7 min at room temperature, the supernatant removed, then centrifuged again at 5,900 x g for 2 
min at room temperature, the supernatant removed, and the pellet stored at -80°C.  Cell stocks 
were prepared by transferring the cells into a freezing medium composed of 50% foetal bovine 
serum, 45% complete medium, and 5% dimethylsulfoxide (DMSO) (Sigma-Aldrich, St Louis, 
U.S.A) and stored in liquid nitrogen. 
For all assays, cells were centrifuged at 149 x g for 7 min at room temperature and pretreated 
with 0.25% Trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco) for 10 min at 37°C with 
5% CO2 in a humidified chamber, to ensure a single cell population.  Cells were washed three 
times in complete medium with centrifugation occurring between washes at 149 x g for 7 min at 
room temperature, suspended in complete medium and counted in a 1:1 solution of cells in 
complete medium and a 0.2% nigrosin (Sigma-Aldrich) solution, using a hemocytometer. Cells 
were then diluted to the cell density noted in each experiment. The remainder of the cells not 
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used for experiments were collected by centrifugation and the pellets were stored frozen until 
needed for later (RNA) analysis. 
2.1.1 GLC20 RBM10 knockdown subline generation 
SCLC GLC20 RBM10 stable KD sublines were generated from passage 7 GLC20 wild type 
cells.  Several different visual dilutions of GLC20 cells were plated in 24 well flat-bottom plates 
(Sarstedt AG & Co., Nümbrecht, Germany) and incubated at 37°C with 5% CO2 in a humidified 
chamber for 24 h.  Half of the cells were then transfected with a control shRNA vector “Hush 
300” (TR30003, Origene Technologies, Inc, Rockville, U.S.A) and the other half with a 50:50 
shRNA mix of “Hush 29” (TI308329, Origene, 5’-
GCCTTCGTCGAGTTTAGTCACTTGCAGGA) and “Hush 30” (TI308330, Origene, 5’-
AGTCACTTGCAGGACGCTACACGATGGAT). These shRNA vectors were previously used 
by Dr. Sutherland 
72
. Hush 29 and 30 both target exon 6 of RBM10 and are not variant specific 
(Figure 1).  Cells were transfected using Lipofectamine 2000 (L2000) (Invitrogen, Life 
Technologies, Burlington, Canada) at a 1:3 shRNA:L2000 ratio.  In summary, per one well, the 
transfection was first started by putting 50 μL Opti-MEM medium (Gibco) into two different 1.5 
mL conical tubes, 1 mixed with 2 μL L2000 and the other with 0.7 μg shRNA (0.7 μg Hush 300 
or 0.35 μg of Hush 29/30 each), and these solutions incubated for 5 min at room temperature.  
The contents of the two tubes were then combined, and the mixture incubated for 20 min at room 
temperature.  The mixture (~100 μL) was then added dropwise onto the cells in one well.  Cells 
were incubated for 48 h at 37°C with 5% CO2 in a humidified chamber. After 48 h, transfected 
cells were selected for seven days using 0.1 μg/mL puromycin (Invitrogen) in complete medium 
at 37°C with 5% CO2 in a humidified chamber. 
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After seven days of selection, cells were treated with a Histopaque solution (Sigma-Aldrich) to 
separate live from dead cells.  Cells were taken from culture and carefully layered on top of the 
Histopaque solution.  The Histopaque/cell solution was then subjected to centrifugation at 233 x 
g for 10 min at 10°C.  The top layer of cells and medium was carefully collected with a plastic 
Pasteur pipette and subjected to centrifugation at 5,900 x g for 2 minutes at room temperature. 
Supernatant was discarded and cells were resuspended in complete medium supplemented with 
0.1 μg/mL puromycin and incubated at 37°C with 5% CO2 in a humidified chamber. The 
surviving cells were then scaled up. The stable negative control shRNA subline was named 
G300.3, and three surviving RBM10 KD sublines were named G29/30.1, G29/30.3 and 
G29/30.4, based on their location on the 24 well plate.  Passage number was recorded post-
transfection, with 0 designating the transfection pass.   
2.2 RBM5 and RBM10 Western blot analysis 
Proteins from GLC20 subline cell pellets were extracted by resuspension of cell pellets in lysis 
buffer, which consisted of 50 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP-40, 100 mM NaF, 1 mM 
EDTA pH 8.0, 1 mM EGTA pH 7.5, and 1X protease inhibitor cocktail (Sigma-Aldrich) in 
deionized (d) H2O.  The suspension of cells was then subjected to centrifugation at 14,000 x g 
for 10 min at 4°C.  The supernatant was kept after centrifugation.  The lysates were then 
quantified using the Bio-Rad (Bio-Rad Laboratories, Hercules, U.S.A) DC Protein Assay Kit 
containing Reagents A, B and S, using bovine serum albumin as the standard (Life 
Technologies). Lysates were stored at -80°C. 
Fifty μg of protein was diluted 1:2 (volume:volume) in sample loading buffer (0.06 M Tris-HCl 
pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue, and 0.05% β-mercaptoethanol in 
dH2O). The samples were separated by electrophoresis through a 4% acrylamide stacking gel 
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(0.125 M Tris pH 6.8, 0.1% SDS, and 4% acrylamide in dH2O) and through a 7% acrylamide 
resolving gel (0.375 M Tris pH 8.8, 0.1% SDS, 7% acrylamide in dH2O) at 40V for roughly 16 h 
in running buffer (0.025 M Tris, 0.2 M glycine, and 0.1% SDS in dH2O). The proteins in the 
resolving gel were transferred to a 0.45 μm polyvinylidene fluoride membrane (PVDF) (Pall Life 
Sciences, GE-Health Science, Little Chalfont, U.K.) via a wet transfer in transfer buffer (25mM 
Tris, 192 mM glycine, 20% methanol in dH2O) at 1 A for 1 h and 15 min at 4°C.  After transfer, 
PVDF membranes were washed sequentially for 15 min, 5 min and 5 min in TBS-T (20 mM 
Tris, 0.5 M NaCl, 0.1% Tween (Bio-Rad) in dH2O), with buffer changed after each wash.  PVDF 
membranes were then blocked with 5% fat-free milk (Carnation® Evaporated Milk, Smuckers® 
Markham, Canada) in TBS-T for 1 h at room temperature.  The PVDF membranes were again 
washed as noted above and probed for ~16 h at 4°C with a 1:2,500 or 1:5,000 dilution of rabbit 
anti-RBM5 LUCA-15-UK (non-commercially available 
8
), a 1:10,000 or 1:2,000 dilution of 
rabbit anti-RBM10 (HPA034472, Sigma-Aldrich or A301-006A-1, Bethyl Laboratories, Inc, 
Montgomery, USA, respectively) or a 1:10,000 dilution of mouse anti-α-tubulin primary 
antibody (sc-8035, Santa Cruz Biotechnology, Inc., Dallas, U.S.A) in 3% milk in TBS-T (the 
position of the epitopes recognized by the RBM antibodies is shown in Figure 1).  The PVDF 
membranes were washed in TBS-T after incubation as noted above and probed for 1 h at room 
temperature with 1:10,000 goat anti-rabbit IgG HRP-conjugated secondary antibody (sc-2004, 
Santa Cruz Biotechnology, Inc.) or 1:10,000 goat anti-mouse IgG HRP-conjugated secondary 
antibody (sc-2005, Santa Cruz Biotechnology, Inc.) in 3% milk in TBS-T.  The PVDF 
membranes were washed again with TBS-T and detection was done by chemiluminescence using 
Amersham ECL Western blotting detection reagents (GE-Healthcare, Little Chalfont, U.K.) and 
capturing the signal by exposure to Amersham Hyperfilm (GE-Healthcare). Longer exposures 
 31 
 
were used when RBM10v2 expression was captured. Film was then developed using a SRX-
101A medical film processor (Konica Minolta Medical and Graphic Inc., Tokyo, Japan) 
2.3 PCR validation of GLC20 RBM5-expressing sublines 
RNA was isolated from cell pellets using Tri-Reagent (Molecular Research Center, Inc., 
Cedarlane, Burlington, Canada). Cells were resuspended in Tri-Reagent solution until pellets 
were visibly dissolved.  After a 5 min incubation at room temperature, 1-bromo-3-chloro-
propane (BCP) (Sigma-Aldrich) was added to the suspension, and incubated for 10 minutes at 
room temperature.  The suspension was then subjected to centrifugation at 16,100 x g for 15 min 
at 4°C. The top (aqueous) layer was collected and the remainder discarded.  RNA was 
precipitated from the solution using 100% isopropanol and then collected after centrifugation at 
16,800 x g for 8 min at room temperature.  The RNA was washed with 75% ethanol in dH2O and 
subjected to centrifugation at 5,900 x g for 5 min at room temperature.  The supernatant was 
discarded and the RNA pellets were air-dried for roughly 10 min, on ice.  RNA was then 
suspended in TE buffer (10 mM Tris-HCl pH 8.0 and 0.1 mM EDTA pH 8.0) and incubated at 
55°C for 10 minutes.  RNase OUT (Life Technologies) was added to the RNA, which was then 
stored at -80°C. 
RNA was quantified using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific, 
Waltham, U.S.A) and only RNA with a 260nm/280nm ratio above 1.8 was used in assays.  
Reverse transcription (RT) was performed using 1 μg of RNA in an RT-buffer (0.526 mM 
dNTPs (New England Biolabs, Inc., Ipswich, U.S.A), 0.01 mM DTT (Invitrogen), 26.3 ng/μL 
Oligo (dT) (AlphaDNA, Montreal, Canada)) in 1X First Strand Buffer (Invitrogen) and dH2O.  
Moloney Murine Leukemia Virus (M-MLV)-Reverse Transcriptase (Life Technologies) was 
added at 10.5 U/μL and the solution was incubated at 42°C for 50 minutes and then at 70°C for 
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15 minutes in a T100 Thermal Cycler (Bio-Rad Laboratories). The cDNA produced was stored 
at -20°C. 
End-point PCR was performed on cDNA using RBM5 and GAPDH gene-specific primers 
(AlphaDNA), detailed in Table 5.  End-point PCR reactions were performed in the following 
reaction mixture: 1X PCR buffer (10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2 pH 8.3) (New 
England Biolabs), 0.2 mM dNTPs (New England Biolabs), 0.4 μM of each primer (AlphaDNA), 
and 50 U/mL Taq polymerase (New England Biolabs).  Reactions were performed in a T100 
Thermal Cycler using the following conditions: 1. 95°C for 5 minutes, 2. gene-specific cycle 
number (25 cycles for GAPDH and 32 or 40 cycle for RBM5) of 95°C for 30 seconds, 59°C for 
GAPDH or 58°C for RBM5 for 30 seconds, and 72°C for 45 seconds for GAPDH and 30 
seconds for RBM5, followed by 3. 72°C for 10 minutes.  PCR products were then diluted with 
6X loading buffer (0.25% bromophenol blue and 30% glycerol in dH2O) and visualized 
following electrophoresis through a 2% agarose gel (Amresco, Inc., VWR International, Radnor, 
Table 5. List of PCR primers and parameters used for GLC20 subline validation 
Gene Primers Exon Ann.
1
  
temp  
Amp.
2
 
size  
GAPDH hmr
3
-GAPDH-F 5’ AACACAGTCCATGCCATCAC  6 59 °C 471 nt 
hmr-GAPDH-R 5’ TCCACCACCCTGTTGCTGTA 7   
      
RBM5 LU15(2) 5’ GCACGACTATAGGCATGACAT 4 58 °C 380 nt 
LU15(3) 5’ AGTCAAACTTGTCTGCTCCA 8/9   
      
 Oligo(dT) 5’ TTTTTTTTTTTTTTTTTTTT    
      
1
 – Annealing, 2 – Amplicon, 3 – Human, mouse and rat homology 
 
U.S.A) in 1X TAE (40 mM Tris-acetate, 10 mM EDTA pH 8.0) buffer containing SYBR Safe 
DNA gel stain (Life Technologies) at 100 V for 50 minutes then imaged using Fluorchem FC3 
(Protein Simple, San Jose, U.S.A).   
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2.4 MTT cell growth assay 
GLC20 cells and sublines were plated at 10,000 cells per well in 96-well flat-bottom plates 
(Sarstedt) at a cell density of 50 cells/μL in eight technical replicates, in complete medium. Cells 
were incubated for 24 h at 37°C with 5% CO2 in a humidified chamber, and then monitored 
every day for 10 days (RBM5 sublines) or five days (RBM10 KD sublines) by MTT assay.  At 
the indicated time intervals, cells were treated with 10 μL of 5 mg/mL MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Reagent (Life Technologies) in PBS 
(Gibco) for 2 h and 45 min at 37°C with 5% CO2 in a humidified container, as previously 
described 
130
.  After incubation time, cells were transferred to a 96-well Vee-bottom plate 
(Sarstedt) and subjected to centrifugation at 500 x g for 5 min at room temperature. Supernatant 
was discarded and the blue formazan precipitate was dissolved in DMSO (BDH Chemicals, 
VWR International, Radnor, U.S.A).  Dissolved crystals were then transferred to a 96-well flat-
bottom plate and incubated at 37°C with 5% CO2 for 10 min in a humidified chamber.  After 
incubation, absorbances were taken from the 96-well plates at 540 nm using a BioTek Synergy 
S4 Spectrophotometer (BioTek Instruments, Inc., Winooski, U.S.A).  Experiments were repeated 
in four biological replicates (RBM5 sublines) or three biological replicates (RBM10 KD 
sublines) represented by different passage numbers.   
Absorbances of each biological replicate were normalized to their respective day 0 absorbance 
value, and the averages of three or four biological replicates for each day are presented.  A Two-
way ANOVA statistical analysis was performed with Bonferroni post-hoc test comparing all 
growth to the pcDNA3 subline for the RBM5 sublines or G300.3 for the RBM10 KD sublines, 
using Graphpad Prism 5 (Graphpad Software, Inc., San Diego, U.S.A). 
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2.5 Cell counting cell growth and cell death assays 
GLC20 cells and RBM5 sublines were monitored every other day for 10 days for cell growth and 
death, using 0.2% nigrosin and a hemocytometer.  Cells were plated at 10,000 cells per well in 
96-well flat-bottom plates at a cell density of 50 cells/μL, in triplicate wells per treatment.  Cells 
were then left for 24 h at 37°C with 5% CO2 in a humidified chamber.  After 24 h, the cells were 
treated with the following conditions: left untreated, saline (0.9% NaCl in H2O) control, 1.0 μM 
cisplatin in saline for 0, 2, 4, 6, 8 and 10 days, or 0.1, 0.5, 10.0 and 100.0 μM cisplatin for 4 and 
8 days (see Table 6 for summary of treatments). Cisplatin (Sigma) was prepared, as previously 
described, in saline at a concentration of 1.0 mg/mL 
131-133
.  The cells were then counted every 
other day by transferring cells to a 96-well Vee-bottom plate and subjecting them to 
centrifugation at 500 x g for 5 min at room temperature.  The supernatant was then discarded and 
cells were treated with 0.25% Trypsin-EDTA for 10 min at 37°C with 5% CO2 in a humidified 
chamber.  Complete medium was then added to cells and they were subjected to centrifugation at 
500 x g for 5 min room temperature.  Cells were then resuspended into complete medium and 
counted in a 1:1 ratio of cells in complete medium and 0.2% nigrosin, using a hemocytometer. 
Live cells were counted as cells with intact membranes, characterized by a lack of blue/purple 
nigrosin within the cells, and dead cells were counted as cells without intact membranes, 
characterized by the presence of blue/purple nigrosin within the cell.  Live cell counts were used 
to monitor cell growth, relative to day 0 counts, and the average of biological triplicates was 
plotted. A Two-way ANOVA was performed with Bonferroni post-hoc analysis, comparing all 
subline cell growth to the pcDNA3 subline, calculated using Graphpad Prism 5. Cell viability or 
percent intact membrane by nigrosin was calculated using the following equation: 
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𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑟 percent intact membrane  by nigrosin 
= # 𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠/(# 𝑙𝑖𝑣𝑒 + # 𝑑𝑒𝑎𝑑 𝑐𝑒𝑙𝑙𝑠) 
Cell viability or percent intact membrane by nigrosin for the 1.0 μM cisplatin values were also 
expressed relative to saline controls, and the average of biological triplicates was plotted. A 
Two-way ANOVA was performed with Bonferroni post-hoc analysis, comparing all subline cell 
viabilities to the pcDNA3 subline, calculated using Graphpad Prism 5. Day four and eight 
cisplatin cell viabilities were made relative to the saline control viability for the calculation of 
EC50 values.  EC50 values were calculated using ‘log(inhibitor) vs. response (three parameters)’ 
on Graphpad Prism 5, and the average of biological triplicates was plotted with the saline control 
represented at 10
-10
 M on the graphs.  A One-way ANOVA was performed with Tukey post-hoc 
analysis, comparing all sublines to the pcDNA3 subline. 
2.6 Confirmation of a 5.0 µM cisplatin EC50 using PARP 
cleavage  
GLC20, pcDNA3, T2 and C4 cells were counted and 1.5 x10
6
 cells were plated into T75 flasks 
(Sarstedt) at a cell density of 50 cells/μL. After a 24 h incubation at 37°C with 5% CO2 in a 
humidified chamber, cells were exposed to 5.0 μM cisplatin for 4 days. Cells were collected by 
centrifugation at 149 x g for 7 min at room temperature followed by 5,900 x g for 2 min at room 
temperature and stored at -80°C. 
Protein lysates were prepared by resuspension of cell pellets in lysis buffer, as noted in Section 
2.2. Fifty μg of protein was electrophoresed and transferred to a PVDF membrane, as noted in 
Section 2.2. PVDF membranes were probed with a 1:2,000 dilution of mouse anti-PARP primary 
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antibody (C2-10, BD Pharmingen, BD Biosciences, San Jose, U.S.A) or a 1:10,000 dilution of 
mouse anti-α-tubulin primary antibody (sc-8035, Santa Cruz Biotechnology, Inc.) in 3% milk in 
TBS-T.  PVDF membranes were washed after incubation and probed for 1 h at room temperature 
with a 1:10,000 dilution of goat anti-mouse IgG HRP-conjugated secondary antibody (sc-2005, 
Santa Cruz Biotechnology, Inc.) in 3% milk in TBS-T.  
Selected protein bands appearing on the autoradiograph were quantified by densitometry. The 
intensity of the 89 kDa cleaved PARP product levels for each subline were expressed relative to 
the α-tubulin control and compared to the pcDNA3 subline.  An average of three biological 
replicates was represented and a One-way ANOVA was performed with Tukey post-hoc analysis 
using GraphPad Prism 5, comparing all sublines to the pcDNA3 subline.   
2.7 Apoptosis Assays 
2.7.1 5.0 µM cisplatin exposure 
GLC20 cells and sublines were counted and 2.0 x10
6
 cells
 
were plated in T75 flasks at a cell 
density of 50 cells/μL.  After a 24 h incubation at 37°C with 5% CO2 in a humidified chamber, 
cells were either exposed to 5.0 μM cisplatin or left untreated for 4 days (see Table 6 for 
summary of treatments).  A fraction of cells was collected by centrifugation at 149 x g for 7 min 
at room temperature and supernatant was discarded, followed by centrifugation at 5,900 x g for 2 
min at room temperature, the supernatant was discarded, and the pellet stored at -80°C.  Another 
fraction of cells was subjected to centrifugation at 149 x g for 7 min at room temperature, 
supernatant was discarded, and the cells were treated with 0.25% Trypsin-EDTA for 10 min at 
37°C with 5% CO2 in a humidified chamber.   
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Table 6. Concentrations of cisplatin tested at different time points 
Experiment Trial Time Points [cisplatin] (μM) 
Cisplatin cell growth 2 2, 4, 6, 8, 10 days 1 
saline 
 
EC50 calculations 
 
 
 
 
 
 
 4, 8 days 0.1 
0.5 
1 
10 
100 
saline 
5 μM cisplatin, PARP cleavage 
 
3 4 days 5 
5 μM cisplatin, PARP cleavage and 
fluorescence microscopy 
 
4 4 days 
 
5 
 
Cells were then washed twice in complete medium and centrifuged at 500 x g for 5 min at room 
temperature, with changes in medium between each centrifugation, then counted in a 1:1 ratio of 
cells in complete medium and 0.2% nigrosin, using a hemocytometer. 0.5 x10
6
 cells were 
resuspended at a 1000 cell/µL density in cold PBS for fluorescence analysis. If fewer than 0.5 
x10
6
 cells were counted, cells were adjusted to a smaller volume at a 1000 cell/µL density in 
cold PBS. 
2.7.2 PARP Western blot analysis 
Protein extracts from cell pellets collected in experiments highlighted in Section 2.7.1 were 
prepared by resuspension of cell pellets in lysis buffer, as noted in Section 2.2. Twenty-five μg of 
protein processed for electrophoresis and transferred to a PVDF membrane as noted in Section 
2.2. PVDF membranes were probed, as noted above in Section 2.6. 
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Film was then scanned and densitometry was performed by using the ‘1D multi – AUTOGRID’ 
analysis tool on the AlphaEaseFC gel documentation system (Alpha Innotech). Comparisons 
were made between the 116 kDa uncleaved PARP product and 89 kDa cleaved PARP product, to 
show percent 89 kDa cleavage product, as follows:  
% 89 𝑘𝐷𝑎 𝑃𝐴𝑅𝑃 𝑐𝑙𝑒𝑎𝑣𝑎𝑔𝑒 =  (
89 𝑘𝐷𝑎 𝑃𝐴𝑅𝑃
𝑇𝑜𝑡𝑎𝑙 𝑃𝐴𝑅𝑃 (116 𝑘𝐷𝑎 +  89 𝑘𝐷𝑎 𝑃𝐴𝑅𝑃)
) ∗ 100% 
An average of three biological replicates was presented and a One-way ANOVA was performed 
with Tukey post-hoc analysis, comparing all the sublines to the pcDNA3 subline.  
2.7.3 Fluorescence microscopy 
Cells previously collected at a density of 1000 cells/µL, as described in Section 2.7.1, were 
washed three times in cold PBS at 5,900 x g for 2 min at room temperature, with changes in cold 
PBS between centrifugations, then resuspended in Annexin-V binding buffer (10 mM HEPES, 
140 mM NaCl, and 2.5 mM CaCl2) at a density of 1000 cells/µL.  Cells were triple stained with 
7-aminoactinomycin D (7AAD) in DMSO, Annexin-V-AlexaFluor® 488 conjugated, and 
Hoechst 33342 Nucblue® Live Cell Stain ReadyProbe Reagent (all Life Technologies) at 0.02 
mg/mL, 5 μL/100μL, and 1 drop/500μL concentrations, respectively, at room temperature for 15 
min in the dark.  Cells were then washed three times in cold Annexin-V binding buffer at 5,900 x 
g for 10 minutes at room temperature, with changes in cold Annexin-V between centrifugations, 
then resuspended in 100 μL of cold PBS.  Samples were loaded into Cytospin™ columns 
(Symport, VWR International, Radnor, U.S.A) pre-loaded with a microscope slide (VistaVision, 
VWR International, Radnor, U.S.A).  Cells were then centrifuged onto the microscope slides at 
500 rpm for 2 min at room temperature in a Shandon Cytospin™ 4 cytocentrifuge (Thermo 
Scientific), rotor # 4127 0806 59930093.   
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Samples on slides were air-dried, then fixed with 4% paraformaldehyde (Sigma-Aldrich) in PBS 
at room temperature in the dark for 10 min.  Slides were washed sequentially in three changes of 
PBS, and then air-dried.  90% glycerol (Sigma-Aldrich) in PBS was added to the samples and a 
No. 1 cover slip (VWR) was placed on top of the sample.  The cover slip was sealed with nail 
polish and the slides stored at 4°C in the dark until visualized (~24 h later). 
Cells were visualized using the Olympus 1x73 Microscope (Olympus Life Sciences, Tokyo, 
Japan).  Fluorophores were excited using Lumen Dynamics Xcite 120 LED (Lumen Dynamics, 
Mississauga, Canada), Olympus LED PS and LBM laser systems (Olympus Life Sciences). 
Fluorescence emission spectra were captured for Hoechst 33342 (Ex: 250 nm/Em: 461 nm), for 
AlexaFluor® 488 (Ex: 495 nm/Em: 519 nm), and for 7-AAD (Ex: 546 nm/Em: 647 nm). In 
addition to fluorophores, cell morphology was observed using phase contrast (images not 
included). Images of the stained cells were captured using the Olympus DP80 camera (Olympus 
Life Sciences) and cellSens Dimensions imaging software (Olympus Life Sciences).  Images 
obtained that were later counted underwent no post-production adjustments.  Images presented in 
figures in this study underwent post-production adjustments using the ‘Adjust Display’ function 
in the cellSens Dimensions imaging software. In brief, background colour intensities were 
excluded from the images using the histogram tool. Colour threshold intensity was then 
increased. These changes were applied to all the images and at the same intensities. 
Exposure times and gain were made constant during the imaging of each biological replicate. 
Although exposure times varied between biological replicates, the Hoechst 33342 stain was 
exposed for roughly 250 ms, the Annexin-V-Alex-Fluor 488 stain was exposed for roughly 2 s 
with a gain of 2X, and the 7-AAD stain was exposed for roughly 800 ms. All images were taken 
using a 40X objective lens. Ten different fields of view were captured as images for all sublines 
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at each time point and a minimum of 300 total events was counted per biological replicate. 
Figure 4 illustrates how each event was defined, ‘Live’, ‘Early Apoptosis’, or ‘Late 
Apoptosis/Necrosis’. In summary, Figure 4A demonstrates examples of ‘Live’ events, defined by 
cells with visually uncondensed nuclei, stained with Hoechst 33342, and a lack of green 
Annexin-V stain or red 7-AAD stain.  ‘Early Apoptosis’ events were defined as cells that had 
either or both green Annexin-V stain (indicative of phosphatidylserine flipping) and condensed 
nuclei (condensed blue Hoechst 33342 staining).  Figure 4Bi and ii provide examples of high and 
low levels of only the green Annexin-V stain, respectively.  Figure 4Biii and iv provide 
examples of high and low levels of chromatin condensation, respectively.  Figure 4Bv provides 
an example of the presence of both the green Annexin-V stain and the chromatin condensation. 
Lastly, ‘Late Apoptosis/Necrosis’ was defined by the loss of membrane integrity, which is 
indicated by the presence of the red stain of 7-AAD (made purple/pink in images), as noted in 
Figure 4C. 
Three biological replicates were performed. For each biological replicate, the events were totaled 
between the ten fields of view counted. A minimum of 300 events was counted per biological 
replicate. Values were then transformed to a percentage of the total number of events that were 
counted, for each biological replicate.  The average of the three biological was presented and 
One-way ANOVA was performed between the sublines for each defined event.  Tukey post-hoc 
analysis was done, comparing all the sublines to the pcDNA3 subline. 
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Figure 4. Sample images to denote the classification of different events refered to in the 
fluorescence microscopy results section.  10 different fields of view were counted for all 
sublines in each treatment and events were counted.  Events were classified into (A) Live, (B) 
Early Apoptosis, and (C) Late Apoptosis/Necrosis.  (A) Live cells were characterized by blue 
nuclei with no other stains that demonstrated no visual condensation of chromatin. (B) Early 
Apoptosis cells were defined as those with green stain (Annexin-V/PS flipping) at high (B i) or 
low (B ii) levels or chromatin condensation (darkening of blue Hoechst stain nucleus) at high (B 
iii) or low (B iv) levels. A combination of Annexin-V binding and chromatin condensation was 
also labeled as Early Apoptosis (B v).  Lastly, (C) Late Apoptosis/Necrosis was defined as any 
cell with the presence of the red 7-AAD stain whether with (C i) or without (C ii) Annexin-V 
stain. All images are samples of those counted.  Images were taken using a 40X objective lens. 
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Chapter 3  
3 Results 
3.1 Confirmation of RBM5 expression 
To understand the role of RBM5 in SCLC, the GLC20 cell line was used.  As noted previously in 
Figures 2 and 3, GLC20 cells do not have RBM5 expression 
15
 and, therefore, provide a useful 
model to monitor how differing levels of RBM5 may affect SCLC cells.  With the use of the 
GLC20 sublines, pcDNA3, T2 and C4, some insight into the functions of RBM5 in SCLC can be 
obtained. Prior to starting experimental studies, RBM5 and RBM10 expression was confirmed 
and examined in the three sublines and wild type GLC20 cells.  RBM5 expression was expected 
to be identical to what was determined by others in the laboratory (Figure 3).  Figure 5 shows the 
levels of RBM5 and RBM10 expression within each subline at the protein level, and RBM5 at 
the mRNA level.  It can be noted that RBM5 expression within each subline was at levels similar 
to those reported by others (Figure 3). RBM5 expression was absent in the wild type GLC20 
cells.  The stable empty vector-transfected subline (pcDNA3) had no RBM5 expression, while 
the stabled pooled population of RBM5-transfected cells (T2), had some RBM5 expression.  The 
stable clonal population of RBM5-transfected cells, C4, had more expression than the T2 
subline. Furthermore, RBM10v2 in the high RBM5-expressing C4 subline appeared to be 
increased when compared to the other sublines.  This observation was further addressed in 
Section 3.5. Figure 5C provides an example of wild type (untransfected) GLC20 cells.  The 
image taken in Figure 5C denotes GLC20 cells roughly at a density that would require 
subculturing.  
 43 
 
 
 
Figure 5. Confirmation of RBM5 and RBM10 expression in GLC20 sublines. (A) RT-PCR 
analysis of RBM5 expression in GLC20, pcDNA3, T2 and C4 sublines with GAPDH control. 
(B) Protein analysis of RBM5 and RBM10 expression (Sigma Antibody) in GLC20, pcDNA3, 
T2 and C4 populations with tubulin control for protein. A longer exposure shows the relative 
abundance of RBM10v1 and RBM10v2 in GLC20 cells. mRNA from Trial #5 was not analyzed, 
as RBM5 protein expression was observed instead, found in Figure 13 (C) Sample image of 
GLC20 cells in culture using a 4X objective lens. 
 
Table 7 highlights the details of each trial that is described in this study.  A ‘trial’ is defined as a 
new subset of previously frozen cells, used for a particular subset of experiments, represented by 
figure.  This information was relevant to understanding whether any variances between trials 
could be explained by the number of times that the cells had been subcultured (represented by 
passage number) prior to the beginning of the experiment. It was important to ensure that all  
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Table 7. Summary of experimental trials and biological replicates 
Trial # Sublines Passage # BR* # Figures - Experiment Thesis Page 
1 GLC20 7-12 1-4 
1-4 
1-4 
1-4 
Figure 7 – MTT cell growth assay 48 
pcDNA3 43-47  
T2 29-32  
C4 14-17 
 
 
2 GLC20 10-12 1-3 
1-3 
1-3 
1-3 
Figure 7 – Cell counting cell growth 
assay 
Figure 8 – Cisplatin cell growth assay 
Figure 9 – Membrane integrity assay 
Figure 10 – EC50 assay 
 
48 
pcDNA3 48-50  
T2 31-33 50 
C4 13-15 
 
54 
57 
3 GLC20 8-12 1-3 
1-3 
1-3 
1-3 
Figure 11– 5.0 μM cisplatin PARP 
cleavage 
60 
pcDNA3 46-50  
T2 30-34  
C4 11-13 
 
 
4 GLC20 10-12 1-3 
1-3 
1-3 
1-3 
Figure 12 – 5.0 μM cisplatin PARP 
cleavage and 5.0 μM fluorescence 
microscopy 
62 
pcDNA3 47-49  
T2 30-32  
C4 13-15 
 
 
5 GLC20 6-12 1-5 
1-5 
1-5 
1-5 
Figure 13 – RBM5 effects on RBM10 68 
pcDNA3 42-48  
T2 27-32  
C4 9-13 
 
 
6 G300.3 1-6 1-3 
1-3 
1-3 
1-3 
Figure 14 – RBM10 KD analysis 71 
G29/30.1 1-6  
G29/30.3 1-5  
G29/30.4 1-4 
 
 
7 G300.3 5-8 1-3 
1-3 
1-3 
1-3 
Figure 15– RBM10 KD effects on cell 
proliferation 
73 
G29/30.1 5-7  
G29/30.3 4-7  
G29/30.4 3-5 
 
 
* denotes ‘Biological replicate’ 
 
experiments were performed with similar passage number in order to control for differences in 
time of propagation or passage number amongst experiments and cell lines.  
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In order to ensure that the expression of RBM5 remained constant between the cell stocks used 
in our experiments, mRNA from nearly all the biological replicates was isolated from the cells 
from each trial as described in Table 7. The mRNA was then transformed into cDNA by reverse- 
transcription, and PCR was carried out. Forty PCR cycles were done to ensure that any residual 
expression of RBM5 in the GLC20 and pcDNA3 control sublines would be detected as this 
could indicate cross-contamination between the sublines.  As noted in Figure 6, RBM5 
expression was found only in the T2 and C4 sublines throughout all the trials.  In all biological 
replicates within each trial, RBM5 expression was present in each RBM5-expressing subline. 
There was no visual presence of RBM5 mRNA expression in the GLC20 and pcDNA3 in any 
trials of the experiments that were performed. 
These RT-PCR experiments ensured that RBM5 expression was monitored within each trial of 
experiments.  The observation of a lack of RBM5 expression within the GLC20 and pcDNA3 
sublines in addition to the expected expression of RBM5 within the T2 and C4 sublines increases 
confidence that the following experiments and results are indicative of the effect RBM5 
expression on cell physiology. This suggests that any differences observed between the sublines 
could be due to the differences in RBM5 expression. 
 
 46 
 
 
Figure 6. RBM5 mRNA expression in each subline for several trials.  End-Point PCR 
analysis was carried out on mRNA extracted from GLC20, pcDNA3, T2 and C4 cell pellets 
collected at the same time as the plating of experiments.  Each trial denotes a set of biological 
replicates.  32 and 40 cycle RBM5 PCR and 25 cycle GAPDH PCR reactions were carried out, 
as shown, for each BR. One technical replicate was performed for each biological replicate. NTC 
stands for ‘no template control’. ‘Thawed T2’ represents an mRNA sample extracted from the 
first passage of T2 cells there were used in the experiments. 
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3.2 Increased RBM5 expression resulted in decreased GLC20 
cell proliferation 
To observe the effect of differing levels of RBM5 expression on GLC20 cell proliferation, two 
assays were employed, MTT and cell counting. RBM5 is a known regulator of the cell cycle, and 
RBM5 overexpression has previously been associated with G1 phase arrest 
53
. RBM5 
overexpression has also been shown interfere with the proliferation of various cell lines, 
including A549 cells (lung adenocarcinoma) 
6,16,17,20,54
.  As a result, it was expected that the 
proliferation of the SCLC cell lines would decrease as RBM5 expression would increase. 
Cell proliferation was first examined using the MTT assay (Figure 7A).  The MTT assay uses the 
addition of MTT reagent (Section 2.4), which is metabolized in functional mitochondria into a 
formazan dye, to provide a colorimetric tool to quantify at 540 nm 
136
. Cell proliferation was also 
determined using a hemocytometer (Figure 7B).  In this case, the number of live cells excluding 
nigrosin was used as a measure of proliferation.  The MTT assay was previously used to examine 
the response of GLC20 cells following their exposure to different reagents 
130,134
.  Cell 
proliferation was monitored every day using the MTT assay (Figure 7A) and every other day by 
cell counting (Figure 7B) for a ten-day period.  In both assays, average values from each day in 
which a measurement was taken was made relative to the values obtained on the first day of the 
experiment (day zero) to demonstrate relative cell growth. 
Figure 7 presents the results obtained from the MTT (trial #1) and cell counting (trial #2) assays.  
The results from the MTT assay (Figure 7A) show that the growth of the high RBM5-expressing 
C4 subline was significantly less than the pcDNA3-transfected RBM5-null subline from day five 
to day ten (day five p<0.01, day six-ten p<0.0001).  The non-transfected wild type GLC20 
subline also showed a significant decrease in cell growth from day eight to day ten of the assay  
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Figure 7. Increased RBM5 expression resulted in decreased GLC20 cell proliferation. 
GLC20, pcDNA3, T2 and C4 GLC20 sublines were grown for 10 days and their growth 
monitored (A) daily by a MTT assay, and (B) every other day by cell counting using a 
hemocytometer. (A) Average of four biological replicates performed in eight technical replicates 
with standard error. (B) Average of three biological replicates carried out in technical triplicate 
with standard error is displayed. A Two-way ANOVA was performed between pcDNA3 and the 
other sublines, with Bonferroni post-hoc analysis, for (A) and (B). *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. 
 
(day eight p<0.01, day nine, day ten p<0.0001), compared to the pcDNA3 subline.  Lastly, the 
low RBM5-expressing T2 subline demonstrated no significant difference in cell growth from the 
pcDNA3 control subline until day ten (p>0.05) in Figure 7A.  
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The results from the cell counting assay (Figure 7B) show that the C4 subline had significantly 
less cell growth when compared to the pcDNA3 subline, from day six to day ten (day six p<0.01, 
day eight, day 10 p<0.0001).  As in the MTT assay, the GLC20 wild type cell line showed a 
significant decrease in cell growth, compared to the pcDNA3 subline but by the later time point 
of day ten (p<0.05) rather than day eight (Figure 7A).  The low RBM5-expressing T2 subline 
showed no growth difference compared to the pcDNA3 subline, in contrast to what was noted by 
MTT.  Using both assays, the results demonstrate that highly increased RBM5 expression 
appears to induce a decrease in GLC20 cell proliferation. 
Following the observation of the effect of RBM5 on GLC20 cell proliferation, the additive effect 
of cisplatin exposure on the role of RBM5 in cell proliferation was investigated.  RBM5 is a 
known modulator of both the cell cycle and apoptosis 
53
, and so this experiment was performed 
to understand whether cisplatin would increase the effect of RBM5 expression on cell 
proliferation.  Cisplatin was chosen as it is commonly used in chemotherapy for SCLC 
104
. Live 
cell counting, as noted above, was used to monitor each subline’s proliferation in the presence of 
a saline control or 1.0 µM cisplatin (in saline).   
As shown in Figure 8A, we noticed that the proliferation of each subline after exposure to saline 
was similar to that of untreated cells found in Figure 7B.  Both the GLC20 and T2 sublines did 
not show a significant difference in cell growth when treated with saline, relative to the pcDNA3 
subline.  Similar to the unexposed cells in Figure 7B, the C4 subline had a significant difference 
in cell proliferation when compared to the pcDNA3 subline, from day six to day ten (day six 
p<0.001, day eight, day ten p<0.0001).  Figure 8B shows that all sublines exhibited a cisplatin-
induced reduction in proliferation over the ten-day period. Both the wild type GLC20 
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Figure 8. RBM5 expression did not induce an additional effect on GLC20 cell proliferation 
decrease in presence of cisplatin. Trial #2 GLC20, pcDNA3, T2 and C4 cell growth was 
monitored by hemocytometer every other day for 10 days after treatment with either (A) a saline 
control, or (B) 1.0 μM cisplatin. (A) and (B) Average of the three biological replicates performed 
in technical triplicate with standard error. (C) Average of all three biological replicates of 1.0 μM 
cisplatin made relative to the saline control of its biological replicate with standard error. A Two-
way ANOVA was performed between pcDNA3 and the other sublines, with Bonferroni post-hoc 
analysis for (A), (B) and (C). */# (where two sublines are significant) p<0.05, *** p<0.001 and 
**** p<0.0001. 
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and pcDNA3 control sublines had similar results for cell proliferation. The T2 and C4 sublines 
showed a greater decrease in relative live cell number in the presence of cisplatin that was 
significant on day ten (both p<0.0001), when compared to pcDNA3-transfected cells.  
To determine if the exposure to cisplatin resulted in an increase of the effect of RBM5 on cell 
proliferation, the results obtained in the presence of 1.0 µM cisplatin (Figure 8B) were 
normalized to those exposed to saline (Figure 8A) and are presented in Figure 8C.  This was 
performed to understand if the reduction in cell proliferation, observed as a loss in relative live 
cell counts, was due to RBM5 expression.  Over the ten-day experiment, a trend appears in 
which the relative cell proliferation of each subline decreased uniformly with no differences.  
However, on day two of the experiment, both the T2 and C4 sublines showed a significant 
decrease in relative cell growth (day two both p<0.05), suggesting an additive effect of cisplatin 
on the RBM5-expressing sublines’ cell proliferation.  The T2 subline also showed a significant 
decrease in relative cell growth on day four (p<0.05), compared to the pcDNA3 subline.  The C4 
subline demonstrated a significant increase in cell growth on day eight (p<0.001), compared to 
the pcDNA3 subline, which differs from the downward trend in each subline.  By day ten, the 
proliferation of the C4 subline was again decreased.  This result may suggest that, in the presence 
of cisplatin, there is a reduction in cell proliferation in the RBM5-expressing sublines early after 
exposure that occurs before RBM5 expression is observed to reduce cell proliferation in the 
untreated cells (Figure 7).  The effect does not occur over a longer period of time, as each subline 
reverts to the observed trend after day six.  Most likely, this is could be simply variation in the 
data over time. 
These results demonstrated that the cell lines with high RBM5 expression exhibit reduced cell 
proliferation, as made evident by the significant decrease in cell growth noted in the C4 
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population (Figure 7).  Clonal variation can also account for these observations in the C4 subline, 
and will be discussed further in the discussion section. In addition, exposure to saline has no 
effect on the proliferation of the sublines (Figure 8A).  In contrast, exposure to cisplatin resulted 
in a reduction of cell proliferation in each subline (Figure 8C), which was observed to be 
significant in the T2 and C4 sublines by day ten, when compared to the pcDNA3 subline. Upon 
comparing the cell proliferation of cells exposed to 1.0 μM cisplatin relative to the saline 
exposed cells, RBM5 expression induced a significant decrease in cell proliferation early after 
exposure, although there was an observed downward trend common in each subline (Figure 8C).  
3.3 RBM5 expression was associated with increased GLC20 
cell death in the presence of cisplatin 
Having noted a significant decrease in cell proliferation in the high RBM5-expressing C4 
subline, but no overall difference in cell proliferation in cisplatin exposed cells, relative to the 
pcDNA3-transfected subline, the effect of RBM5 expression on GLC20 cell death was 
examined.  RBM5 is a modulator of cell death through apoptosis 
46,53
. Therefore, RBM5 
expression may be influencing GLC20 cell death in the presence of cisplatin.  It was anticipated 
that there would be an increase in GLC20 cell death in the RBM5-expressing sublines, relative to 
the expression of RBM5.  
To ascertain whether or not RBM5 increased GLC20 cell death, live and dead cell counts were 
performed every other day for ten days and percent membrane integrity was determined, as noted 
in Section 2.5, using a nigrosin exclusion assay. The percentage of cells with intact membrane is 
surrogate for cell viability. It was observed that roughly 80% of unexposed GLC20 cells and 
sublines retained plasma membrane integrity throughout the ten days of the experiment, as 
shown in Figure 9A.  The control saline exposed cells in Figure 9B were also observed to have 
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maintained roughly 80% of cell membrane integrity through the experiments.  In each of the 
unexposed and saline exposed cells, no subline demonstrated a significant difference in intact 
membrane when compared to the pcDNA3 subline.  The lack of significant differences provides 
evidence that RBM5 expression on its own did not result in a decrease in  cell membrane 
integrity, suggesting there was no increase in cell death. 
In the cisplatin-treated cells, a significant decrease was observed in the percentage of cells with 
membrane intergity, suggesting that cell viability was reduced (Figure 9C).  The GLC20 and 
pcDNA3 sublines reached a minimum of approximately 70% of cells with membrane intergrity 
on day four, that was maintained for the remainder of the experiment.  Both RBM5-expressing 
sublines demonstrated a greater decrease in the percentage of cells with membrane integrity. The 
T2 subline reached a minimum of approximately 50% of cells with intact plasma membranes by 
day eight, increasing slightly thereafter.  The percentage of C4 subline cells with membrane 
integrity continued to decrease throughout the ten-day experiment, reaching a minimum of 
approximately 40% of cells with membrane integrity by day ten.  Both the T2 and C4 sublines 
demonstrated a significant decrease in the percentage of cells with membrane integrity, relative 
to the pcDNA3 subline, starting on day four, and continuing throughout the experiment (Figure 
9C) (T2: day four p<0.05, day six p<0.001, day eight p<0.0001, day ten p<0.01, C4: day four 
p<0.001, days six-ten p<0.0001).  This significant decrease in T2 and C4 subline membrane 
integrity when the cells were exposed to 1.0 μM cisplatin suggests that RBM5 expression 
sensitized cells to death-inducing stresses. 
As shown in Figure 9D, when the percentage of cells with membrane integrity of the cisplatin- 
exposed sublines was compared to those exposed to saline, the GLC20 and pcDNA3 sublines 
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Figure 9. GLC20 cell membrane integrity decreased with RBM5 expression in the presence 
of cisplatin. Trial #2 GLC20, pcDNA3, T2 and C4 membrane integrity was monitored by 
hemocytometer every other day for 10 days and were (A) left untreated, or exposed to either (B) 
a saline control or (C) 1.0 μM cisplatin. Average of the three biological replicates performed in 
technical triplicate with standard error is displayed for each treatment. (D) GLC20, pcDNA3, T2 
and C4 1.0 μM cisplatin was made relative to the saline control for each time point.  Average of 
all three biological replicates of 1.0 μM cisplatin were normalized to the saline control of its 
biological replicate with standard error is displayed. A Two-way ANOVA was performed 
between pcDNA3 and the other sublines, with Bonferroni post-hoc analysis for (A), (B), (C) and 
(D). * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
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showed similar decreases in the percentage of cells with membrane integrity, with a minimum of 
roughly 85% of cells having intact membranes by day two, a level maintained throughout the 
experiment. In contrast, the T2 and C4 sublines had a greater decrease, with a minimum of 
roughly 60% of cells having intact membranes by day eight.  The decrease in the percentage of 
T2 and C4 cells with membrane integrity was significant when compared to the pcDNA3 subline 
from day two to ten (T2: day two p<0.05, days four-eight p<0.0001, day ten p<0.001, C4: day 
two p<0.001, days four-ten p<0.0001).  There were no significant differences between the 
GLC20 wild type and pcDNA3 control sublines. This indicates transfection of cells with the 
empty vector did not affect the cells’ response to 1.0 μM cisplatin exposure. In summary, the 
experimental results presented in Figure 9 demonstrated that in the presence of 1.0 µM cisplatin 
the percentage of cells with membrane integrity decreased for all sublines, with those expressing 
RBM5 resulting in a greater significant decrease.  
To further explore the significant decrease in membrane integrity observed in the RBM5-
expressing sublines, the EC50 or the concentration of cisplatin required to reach 50% relative 
intact membrane was calculated for each subline on day four and day eight. The GLC20 cells 
have previously been documented to have an IC50 of approximately 75.0 µM cisplatin after one 
hour through the use of the MTT assay 130.  In addition to a saline control, cells were exposed to 
increasing concentrations of cisplatin for either four or eight days and cell membrane integrity 
was determined.  Percent intact membrane values were then calculated and expressed relative to 
the saline control for each time point (as previously presented in Figure 9D) and plotted on a 
‘non-linear fit-log(inhibitor) vs response model (3parameters)’ plot in Graphpad Prism 5, to 
obtain the EC50 values.  The saline control was given a concentration of 10
-10 µM cisplatin, since 
the log of zero is undefined.  Figure 10 shows the calculated EC50 values for each four-day 
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exposure (Figure 10A) and eight-day exposure (Figure 10B). Figure 10Ai and Bi show the 
calculated EC50 curves for each subline, with comparisons to the pcDNA3 control subline. The 
GLC20 and pcDNA3 sublines showed no significant viability differences at any concentration of 
cisplatin at either time point. At cisplatin concentrations of 0.5, 1.0 and 10.0 µM cisplatin, both 
the T2 and C4 sublines had significant differences in relative cell membrane integrity, when 
compared to the pcDNA3 subline, after four days (Figure 10Ai) and eight days (Figure 10Bi) 
exposure (day four T2: 0.5 μM p<0.001, 1.0 and 10.0 μM p<0.0001, C4: 0.5 μM - 10.0 μM 
p<0.0001; day eight T2: 0.5 μM p<0.05, 1.0 μM p<0.0001, 10.0 μM p<0.05, C4: 0.5 μM - 10.0 
μM p<0.0001).   At cisplatin concentrations of 0.1 and 100.0 μM, no significant differences, on 
either day, were observed, when compared to the pcDNA3 subline.   
The EC50 value for each subline was then calculated from the curves in Figure 10Ai, Bi, and 
presented as a bar graph in Figure 10Aii, Bii. GLC20 and pcDNA3 sublines were calculated to 
have an EC50 of 17.97 μM and 17.16 μM on day four and 3.58 μM and 3.59 μM on day eight, 
respectively, with no significant differences on either day. In comparison, T2 and C4 sublines 
were calculated to have EC50 values of 4.86 μM and 2.52 μM on day four and 1.74 μM and 1.29 
μM on day eight, respectively.  When compared to the pcDNA3 subline, the EC50 of both the T2 
and C4 sublines showed a significant difference on both day four (T2 p<0.05, C4 p<0.01) and 
day eight (T2 p<0.001, C4 p<0.001).  These results support the earlier observation of decreased 
membrane integrity in the RBM5-expressing sublines, at 1.0 μM cisplatin, as shown in Figure 9, 
suggesting that the observed decrease in cisplatin EC50 is attributable to RBM5 expression. 
Furthermore, neither the T2 nor the C4 sublines showed a significant difference in its EC50 for 
cisplatin on day four and day eight.  However, there was a decrease in cisplatin EC50 in all 
sublines between day four and day eight, suggesting the longer the exposure to cisplatin, the less 
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Figure 10. GLC20 cisplatin EC50 decreased with RBM5 expression. Trial #2 GLC20, 
pcDNA3, T2 and C4 membrane integrity was monitored by hemocytometer after (A) 4 and (B) 8 
days of exposure to a saline control (10
-10
 M cisplatin), and 0.1, 0.5, 1, 10, and 100 μM cisplatin. 
Membrane integrity of each concentration was made relative to the saline control and displayed 
as relative intact membrane by nigrosin (%) over log concentration of cisplatin. (i) Average 
relative intact membrane of three biological replicates performed in technical triplicate with 
standard error and the calculated average EC
50
 (calculated from Graphpad Prism 5, ‘non-linear 
fit–log(inhibitor) vs response (3 parameters)’). (ii) Average EC
50
 of three biological replicates is 
plotted for each subline.  One-way ANOVA was performed, with Tukey post-hoc analysis where 
noted between the sublines. * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
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cisplatin is required to result in a loss of 50% of the cells. This result suggests that RBM5 
expression, no matter the level, is associated with an expression-level dependent reduction in 
cisplatin EC50. 
In summary, these results demonstrate a significant decrease in intact cell membranes in the 
RBM5-expressing T2 and C4 sublines, relative to the pcDNA3 subline in the presence of 1.0 μM 
cisplatin.  Also, there was a significant decrease in the EC50 values of the T2 and C4 sublines, 
compared to the pcDNA3 control, and no change between the pcDNA3 and GLC20 sublines, 
after four and eight days of exposure cisplatin.  When taken as a whole, these observations 
demonstrate that high RBM5 expression induces increased cell death in the presence of cisplatin. 
3.4 Increased RBM5 expression resulted in increased 
apoptotic cell death in GLC20 cells in the presence of cisplatin 
Following the discovery that RBM5 expression in the T2 and C4 sublines resulted in (a) 
significantly increased cell death (measured as decrease in the percentage of cells with 
membrane integrity) (Figure 9) and (b) a significantly decreased cisplatin EC50 (Figure 10), 
further experimentation was carried out to determine whether or not this decrease in membrane 
integrity was due to increased apoptosis.  Since cisplatin commonly kills cells by triggering 
apoptosis 
121,123
, and RBM5 is a modulator of this type of cell death 
46
, it was anticipated that the 
presence of RBM5 in the T2 and C4 sublines was influencing the effect of cisplatin on death 
signalling pathways.   
To first explore whether or not the decreased membrane integrity of the RBM5-expressing 
sublines in the presence of cisplatin was a result of apoptosis activation, cells were exposed to 
5.0 μM cisplatin for four days and PARP cleavage was monitored.  The first preliminary 
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experiment was performed to determine if 5.0 μM cisplatin exposure was sufficient to induce 
apoptosis, and to confirm the T2 subline’s EC50 at day four. Figure 11 highlights the results from 
this experiment.  As shown in Figure 11A, it was observed that there was an increase in the 89 
kDa PARP cleavage product, but no visual decrease in intact PARP (116 kDa).  This observation 
could be due to saturation of the upper PARP band, or due to the capturing of very early 
apoptosis.  Regardless, this was an initial test to confirm previous results, and therefore, 89 kDa 
band intensity measurements by densitometry were expressed relative to α-tubulin for each 
subline, and then normalized to that obtained for the pcDNA3-transfected subline (Figure 11B).   
Although the error bars show a high level of variance (Figure 11B), the densitometry results 
demonstrated an approximately 1.8-fold increase in the 89 kDa PARP cleavage product in the T2 
subline (p=0.0457) and a 5.5-fold increase in the 89 kDa PARP cleavage product in the C4 
subline (p=0.0068), when compared to the pcDNA3-transfected cell line (Figure 11B).  
Furthermore, the level of the 89 kDa PARP cleavage product in the GLC20 and pcDNA3-
transfected cell lines was not significantly different from each other (p=0.4255).  These results 
demonstrated that there was a significant increase in the generation of the 89 kDa product after 
four days of cisplatin exposure in the RBM5-expressing sublines T2 and C4. This was the first 
indication that the increase in cell death, or decrease in cell membrane integrity, that was 
observed in the RBM5-expressing sublines exposed to cisplatin may be due to apoptosis. 
To confirm that the increase in cell death and the increase in the 89 kDa PARP cleavage product 
in the T2 and C4 sublines was through the promotion of apoptosis, further experiments looking 
into other apoptotic markers were performed.  RBM5, as a modulator of apoptosis, has been 
shown to influence many markers of apoptosis such as chromatin condensation and 
phosphatidylserine exposure on the external plasma membrane surface (phosphatidylserine  
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Figure 11. RBM5-related cell death in presence of 5 μM cisplatin corresponded with an 
increase in PARP cleavage. PARP cleavage was monitored in Trial #3 GLC20, pcDNA3, T2 
and C4 cells after treatment with 5.0 μM cisplatin for four days.  (A) One representative 
biological replicate Western blot result is presented at two different exposures.  (B) Densitometry 
of the scanned Western blot autoradiographs of each biological replicate was performed using the 
AlphaEaseFC, ‘1D-Multi’ analysis tool.  Values of 89 kDa PARP cleavage product were 
normalized to the α-tubulin of the biological replicate, and then normalized to the pcDNA3 
control. Average 89 kDa cleavage product of three biological replicates with standard error is 
presented. One-way ANOVA was performed with Tukey post-hoc analysis, between sublines. * 
p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
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flipping or membrane asymmetry) 24,53, and cisplatin is known to kill cells through apoptosis 
121,123.  It was anticipated that the RBM5-expressing sublines (T2 and C4) would show evidence 
of other apoptotic markers in the presence of cisplatin.  Therefore, fluorescence microscopy was 
performed to investigate chromatin condensation and phosphatidylserine flipping (via Annexin-V 
binding), both hallmarks of apoptotic cells 45,48.  In addition, PARP cleavage was again 
monitored, in the same trials (#4) used for fluorescence microscopy. Cells were exposed to 5.0 
μM cisplatin over a period of four days, after which fluorescence microscopy and PARP cleavage 
assays were conducted.  As noted in Section 2.7.3 and Figure 4, several different stains were 
used to distinguish different cellular phenotypes. A summary of the classifications of events was 
presented in Section 2.7.3.   
Figure 12 highlights the results that were obtained from the fluorescence microscopy 
experiments and Western blot analysis of PARP cleavage. Cells from trial #4 were used in these 
studies, as noted in Table 7.  Figure 12A presents sample images of untreated cells incubated for 
four days while Figure 12B presents sample images of cells that were exposed to 5.0 μM 
cisplatin for four days.  Figure 12C shows PARP cleavage by Western blot analysis of the same 
cells for fluorescence microscopy. In the untreated cells, there was no visible chromatin 
condensation (Figure 12A, left most panel), Annexin-V binding (an indication of potential 
phosphatidylserine flipping) (Figure 12A, middle-left panel) or changes in membrane integrity 
(Figure 12A, middle-right panel) for the four sublines.  The merge images provided in the far-
right panels in Figure 12A combine the three stains in one image.  
Cells exposed to 5.0 μM cisplatin for four days (Figure 12B) exhibited differences in phenotypes 
compared to untreated cells (Figure 12A).  In the cisplatin-exposed cells, there were visual 
increases in chromatin condensation, Annexin-V binding (potential phosphatidylserine flipping)  
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Figure 12. Increased RBM5 expression resulted in increased apoptosis in the presence of 5 
µM cisplatin.  Trial #4 GLC20, pcDNA3, T2 and C4 cells were left (A) untreated or (B) treated 
with 5 μM cisplatin and collected after four days for fluorescence microscopy using a 40X 
objective lens (A/B) or PARP cleavage analysis (C i/ii). One representative image of each cell 
line (A) left untreated or (B) exposed to 5 μM cisplatin for four days is presented. Apoptotic 
markers chromatin condensation (Hoechst/blue) and Annexin-V binding (phosphatidylserine 
flipping) (Annexin-V/green) as well as late apoptosis/necrosis marker of presence of red 7-AAD 
stain were analyzed by fluorescence microscopy. (C i) One representative biological replicate 
Western blot result is presented.  (C ii) Densitometric analysis of each biological replicate was 
done using AlphaEaseFC, ‘1D-Multi’ analysis tool. Percent 89kDa PARP cleavage product 
[(89kDa cleaved PARP/total PARP)*100] analysis of three biological replicates with standard 
error of the 5 µM cisplatin treated and untreated cells is presented. (C iii) Average number of 
fluorescence microscopy events pooled into Live (only blue), Early Apoptosis (condensed blue 
and/or green) and Late Apoptosis/Necrosis (Red) performed in three biological replicates, each 
with 10 different fields of view, with standard error of the 5 μM cisplatin and untreated cells. 
One-way ANOVA was performed with Tukey post-hoc analysis, between sublines. * p<0.05 and 
*** p<0.001. 
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Figure 12.  Increased RBM5 expression resulted in increased apoptosis in the presence of 5 
µM cisplatin. 
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Figure 12. Increased RBM5 expression resulted in increased apoptosis in the presence of 5 
µM cisplatin. 
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and loss of membrane integrity that was even greater in the C4 subline.  These markers suggest 
that in the high RBM5-expressing subline exhibited an even greater decrease in ‘Live’ cells and 
an increase in the number of cells exhibiting ‘Early Apoptosis’ or ‘Late Apoptosis/Necrosis’.  In 
addition, it was noted that the two RBM5-null sublines (GLC20 and pcDNA3) had larger nuclei 
than the two RBM5-expressing sublines (T2 and C4) when exposed to cisplatin.  This 
observation was not quantified, however may possibly suggest that there is less chromatin 
condensation or apoptosis in the absence of RBM5 expression. 
The PARP cleavage results are presented in Figure 12C.  In this trial, expression of the 89 kDa 
PARP cleavage product was quantified as a percentage of the uncleaved product, rather than 
expression due to the visual decrease in the 116 kDa full-length PARP noted in the C4 sublines.  
This differed from what was noted and quantified in Figure 11, which was also performed with 
5.0 μM cisplatin exposure after four days.   
Overall, cells that were left unexposed for four days maintained low levels of PARP cleavage 
(4% 89 kDa PARP cleavage) (Figure 12Cii), high levels of ‘Live’ cells (85% of events), and low 
levels of ‘Early Apoptotic’ and ‘Late Apoptotic/Necrotic’ cells at roughly 11% and 4% of events, 
respectively (Figure 12Ciii).  There were no significant differences between the sublines, 
signifying no effect of RBM5 in the absence of cisplatin.  However, when exposed to 5.0 μM 
cisplatin for four days, differences between the sublines arose.  Both the GLC20 and pcDNA3-
transfected sublines demonstrated roughly 7% PARP cleavage, with no significant difference 
between the sublines.  The T2 subline had 1.6-fold higher PARP cleavage relative to the 
pcDNA3-transfected subline (11% vs 7%, respectively), although this difference was not 
significant.  The high RBM5-expressing subline, C4, demonstrated roughly 45% PARP cleavage, 
which was significantly higher than that of the pcDNA3-transfected cells (p<0.001).  This 
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observation was further supported by the fluorescence microscopy results in Figure 12Ciii, as the 
percentage of ‘Live’ C4 cells was significantly reduced to roughly 50% compared to the 
pcDNA3-transfected control cell line value of 70% (p<0.001).  In addition, there was a 
significantly higher percentage of ‘Early Apoptotic’ and ‘Late Apoptotic/Necrotic’ C4 cells 
compared to the pcDNA3-transfected subline [30% versus 19% cells (p<0.05) and 19% versus 
10% cells (p<0.05), respectively].  The GLC20 and T2 sublines showed no significant 
differences relative to the pcDNA3-transfected subline in terms of PARP cleavage or any of the 
three fluorescence microscopy categories.  Each of the GLC20, pcDNA3 and T2 sublines had 
70% ‘Live’ cells, 20% ‘Early Apoptotic’ cells, and 10% ‘Late Apoptotic/Necrotic’ cells. In 
comparison, the T2 subline had a significant increase in PARP cleavage relative to the pcDNA3-
transfected cells, as shown in Figure 11.  This difference was not further investigated. 
In summary, the results presented in Figure 11 and Figure 12 indicate that the increase in cell 
death (Figure 9 and 10) observed in the RBM-expressing sublines (T2 and C4) was due to 
increased apoptosis. The high RBM5-expressing C4 subline had considerably higher PARP 
cleavage (Figure 11 and Figure 12Ci/ii), chromatin condensation, and phosphatidylserine 
flipping (Figure 12A/B) compared to the pcDNA3-transfected subline.  These observations are 
consistent with the activation of apoptosis.  The T2 subline demonstrated a significant increase in 
the 89 kDa PARP cleavage product relative to the pcDNA3-tranfected subline (Figure 11) but no 
significant increase in PARP cleavage or other apoptotic events in Figure 12. The low level of 
RBM5 expression in the T2 subline may explain the discrepancy in these results. However, when 
taken as a whole, there appeared to be a positive relationship between RBM5 expression and an 
increase in apoptosis in the presence of cisplatin.  
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3.5 RBM5 expression affected RBM10v1/v2 expression levels 
in GLC20 cells 
In the course of our studies aiming at elucidating the function of RBM5 in GLC20 cells, we 
observed that the expression of RBM5 was accompanied by a change in the protein levels of 
different RBM10 variants.  As noted earlier, RBM10 is a functional homologue of RBM5 that 
modulates apoptosis 
72
.  RBM5 is also known to be involved in the regulation of the expression 
of various genes via alternative splicing 
60,61
. It was observed that in the high RBM5-expressing 
C4 subline, there was an increase in RBM10v2 protein expression and a decrease in RBM10v1 
protein expression (Figure 5B). As this may be indicative of alternative splicing of the RBM10 
transcript by RBM5, this was further analyzed by a set of Western blot analysis of five 
biologically independent extracts of the above cell lines, using duplicate determinations.  
Figure 13 highlights the work completed to investigate the association between increased RBM5 
expression and a change in RBM10v1/v2 expression. Trial #5 cells were used for the analysis, as 
outlined in Table 7.  In Figure 13A, representative Western blot results are presented. It should 
be noted that the exposure time to capture RBM10v2 as much longer than that of RBM10v1, as 
there was a much greater amount of RBM10v1 within the GLC20 cell system (Figure 5). Due to 
RBM10v1 saturation in RBM10v2 exposures, true RBM10v1/v2 ratios could not be presented. 
Therefore, while relative values of RBM10v1 and v2 expression were presented, these results 
should be taken as hypothetical to what may be truly occurring. In the C4 subline there appears 
to be a relative increase in RBM10v2 protein expression and a decrease in RBM10v1 protein 
expression.  Densitometry was performed on each set of technical duplicates for each biological 
replicate and the average of these five biological replicates was quantified (Figure 13B). When 
comparing RBM10v1/v2 expression in the C4 subline to that in the pcDNA3 subline, there was a  
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Figure 13. Increased RBM5 expression influenced an increase in RBM10v2 and a decrease 
in RBM10v1 protein expression. RBM10v1/v2 protein expression was monitored in GLC20, 
pcDNA3, T2 and C4 cells using the Sigma RBM10 antibody. (A) One representative Western 
blot result is presented for RBM10v1/v2, RBM5 and α-tubulin. RBM10v2 was captured using a 
longer exposure as mentioned previous in Figure 6. (B) Densitometric results of the average 
RBM10v1/v2 expression of three biological replicates each performed in technical duplicate was 
performed using AlphaEaseFC, ‘1D-Multi’ analysis tool.  Values of RBM10v1 and RBM10v2 
were normalized to the α-tubulin of each biological technical duplicate, and then made relative to 
the pcDNA3 controls. Standard error is presented.  One-way ANOVA was performed with Tukey 
post-hoc analysis, between sublines. * p<0.05 and *** p<0.001. 
 
significant 1.5-fold high expression (52%) of RBM10v2 in C4 cells than pcDNA3-transfect cells 
(p<0.001).  RBM10v1 protein expression in the C4 subline decreased by roughly 27% relative to 
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pcDNA3-transfected cells, which was also significant (p<0.05).  Although the increase in 
RBM10v2 expression was not equivalent to the decrease in RBM10v1 expression, there was a 
significant change in RBM10v1/v2 protein expression induced with increased RBM5 expression 
(C4 subline). Due to the reciprocal nature of the changes in expression between RBM10v1 and 
RBM10v2, it was postulated that increased RBM5 expression influenced changes in RBM10 
alternative splicing. These results suggest that RBM5, above a certain threshold level, could 
regulate RBM10 alternative splicing, promoting increased RBM10v2 expression and decreased 
RBM10v1 expression.  Alternatively, RBM5 could also potentially differentially modulate the 
stability of the mRNA encoding these RBM10 isoforms. 
3.6 RBM10v1 knockdown induced a decrease in GLC20 cell 
proliferation 
Following the observation that the increased RBM5 expression found in the C4 subline 
influenced RBM10v1/v2 expression, further studies were carried out to observe the effect of 
changed RBM10 expression on the GLC20 cells.  RBM10 is a modulator of apoptosis, and has 
been documented to influence cell proliferation 
56,72
. As it was observed that there was a decrease 
in RBM10v1 expression in the RBM5-expressing C4 subline, RBM10 knockdowns (KDs) were 
performed. RBM10v1 was not specifically targeted in this study as the shRNA used targeted 
exon 6 of RBM10 
72
.  Although this would target both RBM10v1/v2, due to the almost exclusive 
expression of RBM10v1 in the GLC20 cells (Figure 5), all decreases in RBM10 protein were 
reported as RBM10v1, and any effect that was observed was assumed to be due to decreased 
RBM10v1 expression.  It should be noted that the presence of RBM10v2 expression presented in 
Figure 13 was due to a longer exposure.  Further analysis of the effect of RBM10 KDs on cell 
proliferation was performed using the MTT assay. Effects of RBM10 KDs were compared to 
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previously described effects of high RBM5 expression (C4 cells), to see if increased RBM5 
expression and decreased RBM10v1 expression had similar effects. 
Stable RBM10 KDs were produced as noted in Section 2.1.1.  As previously described, GLC20 
cells were subject to transfection with two RBM10 knockdown shRNA plasmids, which together 
were termed 29/30, and targeted exon 6 of RBM10. GLC20 sublines were then selected with 
puromycin and the surviving sublines characterized for RBM10v1 protein expression by Western 
blot analysis. Three RBM10 KD sublines were produced, termed G29/30.1, G29/30.3 and 
G29/30.4.  A control subline was also produced, termed G300.3, using the shRNA scramble 
control plasmid.   
Figure 14 highlights RBM10v1 protein expression in each of the sublines produced.  Trial #6 
cells were used for these experiments, as noted in Table 7.  Figure 14A shows a decrease in 
RBM10v1 expression in G29/30.3 subline and an even greater decrease in G29/30.4 subline.  
Densitometry was performed on three biological replicates, performed in technical duplicate, and 
presented in Figure 14B as expression relative to G300.3 scrambled control subline RBM10v1 
protein expression. Both G29/30.3 and G29/30.4 cells had significantly lower RBM10v1 protein 
expression relative to G300.3 subline, with 55% (p=0.0026) and 16% (p=0.0033) of control 
cells, respectively. The G29/30.1 subline demonstrated a great variance in protein expression, 
and had no significant decrease in RBM10v1 expression relative to G300.3 (99% expression, 
p=0.9836).   
The effect of the RBM10 KD on cell proliferation was analyzed by MTT assay, which was 
previously used to observe the effect of RBM5 expression on cell proliferation (Figure 7A). All 
four sublines produced (G300.3, G29/30.1, G29/30.3 and G29/30.4) were used in the MTT  
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Figure 14. RBM10v1 expression in GLC20 RBM10 KD sublines. RBM10v1 expression was 
monitored in the G300.3, G29/30.1, G29/30.3 and G29/30.4 sublines using the Bethyl RBM10 
antibody. (A) One representative Western blot result is presented for RBM10v1 and α-tubulin 
protein expression. (B) Densitometric results of the average RBM10v1 expression of three 
biological replicates performed in duplicate was performed using the AlphaEaseFC, ‘1D-Multi’ 
analysis tool.  Values of RBM10v1 were normalized to the α-tubulin of each biological replicate, 
and then made relative to the G300.3 control subline. Standard error is presented.  Subline 
expression levels were compared using the Student’s unpaired t-test, between sublines. ** 
p<0.01.  
 
assays. Cell growth was monitored daily for five days, with absorbance readings taken each day.  
These absorbances were then made relative to the day zero value of the respective subline and 
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presented as relative absorbances.  The experiment was performed three times, each performed 
with eight technical replicates.   
Figure 15 presents the results from the MTT experiments.  Trial #7 cells were used for these 
experiments, as noted in Table 7. The G300.3 control and G29/30.1 sublines both had similar 
cell growth rates. This result was anticipated as both sublines had nearly identical levels of 
RBM10v1 protein expression (100% versus 99%).  However, the G29/30.3 and G29/30.4 
sublines both displayed significant differences in cell growth relative to the G300.3 control 
subline. G29/30.3 cells displayed reduced growth compared to G300.3 cells throughout the five 
days; however, G29/30.3 cells also had a greater degree of variance relative to the other sublines.  
As a result, G29/30.3 only demonstrated a significant difference in cell proliferation on day five 
of the experiment (p<0.05), when compared to the G300.3 control. G29/30.4 demonstrated the 
greatest difference in cell growth, with significant differences on day four and day five (p<0.01 
and p<0.0001, respectively), when compared to the G300.3 control. These results suggest that a 
RBM10 KD results in a decrease in GLC20 cell proliferation and were not anticipated. 
Furthermore, this decrease in cell proliferation was related to the level of RBM10 KD, as the 
G29/30.3, with 55% RBM10v1 protein expression, displayed a significant difference in cell 
proliferation later than G29/30.4, which had only 16% RBM10v1 protein expression. In 
summary, these results indicate that a decrease in RBM10v1 protein expression resulted in a 
decrease in GLC20 cell proliferation and, therefore, RBM10 may be directly or indirectly 
involved in the regulation of cell proliferation. 
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Figure 15. Decreased RBM10 expression was associated with decreased GLC20 cell 
proliferation. G300.3, G29/30.1, G29/30.3 and G29/30.4 were grown for 5 days and cell growth 
was monitored daily using an MTT assay.  Proliferation was plotted relative to day 0. The 
average of three biological replicates performed in eight technical replicates with standard error 
is presented. A Two-way ANOVA was performed between the G300.3 and other sublines, with 
Bonferroni post-hoc analysis. * p<0.05, ** p<0.01, and **** p<0.0001. 
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Chapter 4  
4 Discussion 
Due to the fact that lung cancer is the leading cause of cancer deaths in Canada, there is a 
growing need to investigate the underlying mechanisms of lung cancer development and 
response to chemotherapy. Understanding the roles of various lung cancer tumour suppressor 
genes would provide insight into lung cancer incidence and progression and highlight potential 
biomarkers. In this study, we set out to further understand the function of RBM5 within the 
SCLC model.  RBM5 has been identified as a modulator of apoptosis, a regulator of the cell 
cycle, and is involved in the alternative splicing of various pre-mRNAs 
7,61,53,46,60
. RBM5 has also 
been characterized as a putative lung cancer tumour suppressor gene as its location on the short 
arm of chromosome 3 often undergoes allelic loss in many cancers, resulting in decreased 
expression 
25
.  The downregulation of RBM5 is considered a common marker of malignancies, 
including lung cancers 
22,38,39
. Decreased RBM5 expression has also been demonstrated as a 
characteristic of a cell line displaying cisplatin resistance 
17
.  Understanding the function of 
RBM5 in a lung cancer model system may provide further insight into its role in general and an 
explanation as to why the gene is commonly downregulated in lung cancers. Using a SCLC cell 
line that is RBM5-null, GLC20, we aimed to understand the effect of RBM5 expression, at two 
levels: on cell death (specifically apoptosis) in the presence of cisplatin, and on cell proliferation.  
It was anticipated that we would observe a positive relationship between RBM5 expression and 
apoptosis induction and a negative relationship between RBM5 expression and cell proliferation.  
As anticipated, RBM5 expression resulted in changes in GLC20 cell proliferation and cell death.  
High RBM5 expression (C4 subline) resulted in a significant decrease in proliferation (Figure 7) 
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and, in the presence of cisplatin, a further decrease in cell proliferation (Figure 8) and increased 
cell death (Figures 9 and 10) relative to the control pcDNA3-transfected subline. The increase in 
cell death was determined to be apoptotic in nature (Figures 11 and 12).  High RBM5 expression 
also resulted in a decrease in RBM10v1 and an increase in RBM10v2 expression (Figure 13), 
which was not anticipated. This warranted further investigation into the function of RBM10 
(Figures 14 and 15).  In addition, although it was hypothesized that the effects of RBM5 would 
be directly proportionate to its expression, this was not the case in all experiments; however, as 
high RBM5 expression was always associated with increased cisplatin-mediated apoptosis and 
decreased cell proliferation. 
4.1 Physiological relevance 
The GLC20 sublines were used as an in vitro model to compare the functional consequences of 
differing RBM5 expression levels and was not intended to reflect an in vivo model. An argument 
could be made that the expression levels of RBM5 in the C4 population may be beyond what is 
physiologically relevant. In vivo, RBM5 expression exists at varying levels in different tissues
 
9,15
, meaning that it is of substantial importance to understand the effects of differing RBM5 
expression levels. Therefore, it is unnecessary to argue the physiological relevance in the context 
of this in vitro study. 
All of the experiments in this study were performed in vitro.  Therefore, the results that were 
observed may not apply in vivo where a multitude of other factors such as tumour size, 
neighboring cells, and the tumour microenvironment may affect the outcomes. For instance, 
there was a significant increase in ‘Late Apoptotic/Necrotic’ cells in the C4 subline relative to 
the pcDNA3-transfected subline (Figure 12C).  In culture, there are no macrophages to uptake 
the cells undergoing apoptosis, resulting in the cells going through secondary necrosis.  We 
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cannot ascertain whether the effects observed in this study in vitro, such as increases in apoptotic 
and necrotic cells, would result in similar outcomes in vivo. However, it should be noted that 
RBM5 expression decreases in many primary cancer tissue samples 
16,19,21,22,23
.  In fact, RBM5 is 
one of nine genes that are downregulated as part of a 17-gene metastatic signature in solid 
tumours 
38,
 and decreases in RBM5 expression in lung tumours was associated with an increase 
in expression of pro-metastatic protein 
40
.  Considering the loss of heterozygosity at 3p21.3 (to 
which RBM5 maps) occurs in the majority of lung cancers 
15
, it could be speculated that RBM5 is 
potentially one of many genes in which decreased expression is vital for lung cancer tumour 
incidence, progression, aggression, and metastasis.  This speculation concurs with the results 
obtained in this study, demonstrating that cell death and cell proliferation were influenced by 
changes in RBM5 expression.  In order to fully understand the role of RBM5 expression in vivo, 
experiments utilizing mouse models should be performed. An example of an appropriate study 
would be the one performed by Shao et al in 2012, in which RBM5-transfected A549 cells 
resulted in decreased tumour growth when compared to non-transfected A549 cells in mice
 17
.  
4.2 RBM5 expression level and clonal effects 
We anticipated that alterations in cell proliferation, membrane integrity, and apoptosis would be 
dependent on RBM5 expression levels.  We initially thought that any changes observed would 
manifest in proportion to gradual changes in RBM5 expression levels, but we were also aware 
that these changes may have required an absolute or threshold RBM5 expression level (C4 
subline) before they became observable.  Decreases in cell proliferation in the presence of 
cisplatin (Figure 8), membrane integrity/cell death (Figure 9), cisplatin EC50 (Figure 10), and 
increases in PARP cleavage (Figure 11) demonstrated a positive relationship with increased 
RBM5 expression levels.  There were some instances where the low-RBM5 expressing T2 
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subline did not demonstrate any effects.  In those instances, only the high RBM5-expressing C4 
subline demonstrated changes in cell proliferation (Figure 7), apoptosis (Figure 12), and 
RBM10v1/v2 expression (Figure 13), suggesting that in these cases, a specific threshold of 
RBM5 may be necessary.  Our results suggest that high levels of RBM5 expression are required 
to affect cell proliferation and alternative splicing, but in some instances, minor changes in 
RBM5 expression can influence cisplatin-mediated cell death. The effect of RBM5 expression 
on increasing the number of cells undergoing apoptosis appeared to either relate to RBM5 
expression level (Figure 11) or to a threshold of RBM5 expression (Figure 12).  This anomaly 
could be explained by the use of two different cell populations for the separate experiments.  
However, the experiment performed in Figure 12 demonstrated more apoptotic characteristics 
(chromatin condensation, membrane asymmetry, and PARP cleavage), which could be a more 
representative test of apoptosis in the GLC20 cells in comparison to the experiment performed in 
Figure 11 (PARP cleavage).  Furthermore, the 116 kDa PARP band was not taken into account 
in Figure 11 due to a lack of an observed decrease.  This may hint at a potential experimental 
error such as film saturation, further suggesting Figure 11 may not be the best representation of 
what is occurring within this system.  Due to these observations, it may be suggested that 
apoptosis in the GLC20 cell system requires a specific RBM5 expression level to manifest itself.  
To identify if and when a threshold of RBM5 expression is required for apoptosis, we could 
repeat our experiments using a larger number of stable GLC20 sublines with incrementally 
varying levels of RBM5 expression. Nonetheless, all of the significant effects observed in this 
study were related to the high RBM5 expression in the C4 subline. 
Throughout this study, clonal effects must be taken into consideration when attributing specific 
changes in the C4 phenotype to RBM5 expression. Clonal effects can be described as the 
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propagation of cellular changes that are not due to overexpression of a gene but rather the 
random integration of the plasmid DNA into the genome of a single cell 
137,138
.  The integration 
of the plasmid DNA within the genome could have changed the expression of other growth 
regulatory genes (oncogenic or tumour suppressor genes), leading to a unique phenotype only 
observed in the C4 subline.  In addition, the plasmid DNA could have changed repressor or 
promoter functions of similar genes. Therefore, it was possible that the single clone used to 
produce the C4 subline may have had a strongly reduce growth rate (Figure 7) independent of 
RBM5 expression levels. To minimize the confounding effect of clonal variation, described as 
the propagation of a rare variant in the population, which is not reflective of the entire population 
137
, similar passage numbers were used throughout the experiments (Table 7).  However, all of 
the results observed using the C4 subline are consistent with other studies that examined RBM5 
overexpression, such as decreased cell proliferation, increased sensitivity to chemotherapy and 
increased apoptosis in the presence of a stressor 
7,8,11,17,20,24,51,53,55
.  This suggests that the changes 
observed in this study were, in fact, due to high RBM5 expression in the C4 subline and not 
necessarily clonal effects.  Further studies in this area should attempt to use more than one clonal 
population from both the RBM5-expressing and non-expressing sublines.  The use of an 
inducible expression system, where the level of RBM5 expression can be controlled, would also 
help to rule out any clonal effects. 
4.3 Role of RBM5 as a putative lung cancer tumour 
suppressor gene 
As mentioned in Dr. Sutherland’s review in 2010, RBM5 is considered to be a putative lung 
cancer tumour suppressor gene 
25
. Using a SCLC cell line, we supported the role of RBM5 as a 
potential lung cancer tumour suppressor gene since high RBM5 expression reduced cell 
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proliferation (Figure 7) and increased cell death (Figures 9 and 10), which was determined to be 
apoptosis (Figures 11 and 12). This was further confirmed in similar studies using other lung 
cancer cell lines such as A549 (adenocarcinoma), and H1299 (NSCLC) cells 
53,54
.  In addition, 
many RBM5 overexpression studies have been performed in other cancer cell lines such as those 
performed in HT188 (human fibrosarcoma), A9 (mouse non-malignant fibrosarcoma), PC-3 
(prostate cancer), Jurkat (T-lymphocyte) and CEM-C7 (human leukemia) cells, demonstrating 
that RBM5 may function as a tumour suppressor gene via the reduction of cell proliferation or an 
increase in apoptosis 
6,7,16,17,52,53,55
. Although the downregulation of RBM5 occurs in lung cancer 
most often, RBM5 could be considered a putative general tumour suppressor gene. The reduction 
of RBM5 expression has been established in various carcinomas other than lung cancer 
16
 
including vestibular schwannomas 
19
, cancerous prostatic tissue 
20
, biliary tract cancers 
21
, 
pancreatic ductal adenocarcinomas 
22
, and stage III ovarian carcinomas 
23
, when compared to 
adjacent normal tissues.  Furthermore, the overexpression of RBM5 in A549 xenografts in 
BALB/c mice resulted in decreased tumour growth 
17
, further supporting the role of RBM5 as a 
putative tumour suppressor gene. However, to conclusively demonstrate the role of RBM5 as a 
tumour suppressor gene, RBM5 knockdown studies in tumour xenografts should be performed, 
such as those performed in 2016 that demonstrated the role of RBM10 as a tumour suppressor 
gene 
139
.  If the knockdown of RBM5 expression resulted in an increase in tumour growth, in 
addition to other studies such as this one, one could conclusively state that RBM5 is a tumour 
suppressor gene. 
In this study, the changes in cell proliferation, membrane integrity, apoptosis and RBM10 
expression were proportionate to RBM5 expression levels, suggesting that the potential role of 
RBM5 as a tumour suppressor is dependent on its expression. 3p21.3, the region which RBM5 
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maps to, is known to undergo a loss of heterozygosity (the loss of one functional allele out of 
two) in 95% of SCLC and 70% of NSCLC relative to normal tissue 
15,30,32
.  In NSCLC, relative 
to neighbouring tissue, RBM5 expression was reduced by 82% and 73% at the mRNA and 
protein levels, respectively 
16
. It has been suggested that genes within this region, including 
RBM5, exhibit haploinsufficiency 
15,31,33
.  Haploinsufficiency is defined as the incapability of one 
functional allele to produce the protein required to maintain normal function.  Therefore, in the 
case of RBM5, the loss of heterozygosity at 3p21.3 results in the loss of one functional allele, 
which does not produce enough RBM5 to maintain tumour suppressor function.  Consequently, 
similar to what was observed in this study, low RBM5 expression (such as the T2 subline in this 
study, or lost in tissues that underwent loss of 3p21.3 heterozygosity) results in a decrease in 
RBM5 tumour suppressor function.  This would suggest that RBM5 does not follow Knudson’s 
two-hit hypothesis for classic tumour suppressors, requiring both alleles to be non-functional in 
order for the onset or progression of cancer, such as RB1, and instead is similar to FHIT or 
CDKN1B which also demonstrate haploinsufficiency 
140,141
. We can postulate that loss of 
heterozygosity at 3p21.3 results in decreased RBM5 expression, impairing its function as a 
tumour suppressor gene in lung cancer, specifically in regulating cell proliferation and the 
activation of apoptosis.  
4.4 RBM5 regulation of cell proliferation 
We discovered that increased RBM5 expression resulted in decreased GLC20 cell proliferation 
(Figure 7). In A549 cells, the increase in RBM5 expression was demonstrated to induce G1 cell 
cycle arrest, thereby providing a possible mechanism to explain the decrease in cell proliferation 
53
.  Based on previous research, RBM5 may have the ability to alter cell proliferation though the 
alternative splicing of genes related to cell proliferation pathways 
57,60,61
.  RBM5 has been shown 
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to influence specific pathways such as EGFR/KRAS and Wnt/β-catenin in other systems and, 
therefore, RBM5 may also play a direct or indirect role in these pathways in the GLC20 model 
6,18,22,39,42
.  However, the role of RBM5 in the EGFR/KRAS pathway is debatable. Interestingly, 
in H1975 lung adenocarcinoma cells, changes in EGFR expression had no effect on RBM5 
expression 
36
. In contrast, changes in RBM5 expression in A549 cells were associated with 
decreases in EGFR expression, suggesting RBM5 may affect EGFR expression upstream by 
affecting the processing of the transcript 
41
.  RNA-seq results from Dr. Sutherland’s lab show a 
significant decrease in KRAS expression between the pcDNA3-transfected and C4 sublines 
(unpublished), supporting the notion that RBM5 influences KRAS expression.  Further studies to 
elucidate that pathway(s) by which RBM5 may influence cell proliferation in the C4 subline 
should examine changes in EGFR/KRAS or Wnt/β-catenin expression and pathway-related 
protein expression.  Analysis of RBM5 specific alternative splice targets within these pathways 
would also aid in determining whether these changes are directly or indirectly influenced by 
RBM5 expression. 
Interestingly, the pcDNA3-transfected and T2 sublines demonstrated greater cell proliferation 
than the wild type GLC20 cells (Figure 7).  This increase could be attributed to the transfection 
process, resulting in an increase in stress within the cells.  Increased stress could have caused an 
increase in mitochondrial activity, which the MTT assay measures 
136
, resulting in a greater 
increase in cell proliferation (Figure 7A).  However, the cell counting experiments that were 
performed (Figure 7B) suggest that the differences between the sublines are true.  
4.5 The role of RBM5 in cell death 
In this study, we demonstrated the importance of RBM5 expression within cell death and, more 
specifically, apoptotic cell death in the GLC20 cell model. These results suggest that RBM5 
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expression is enough to influence the survival of the cells, but a higher expression level increases 
the likelihood of apoptosis activation in this model. This difference could indicate a relationsip 
between changes in RBM5 expression and cells undergoing cell death, where cell death is 
proportionate to RBM5 expression level, but the activation of apoptotic cell death requires a 
specific threshold.  A potential test for this could be through the use of an inducible promoter 
that ables one to have varying levels of RBM5 expression in the same cell line. 
While only cisplatin was used to induce cell death in this study, it can be suggested that the 
RBM5-related cell death observed in this study was not cisplatin-specific.  Activation of 
apoptosis has previously been observed in other cancer cell lines with other stressors such as 
TNF-α, Fas ligand, TRAIL death receptor, and staurosporine as well as cisplatin when RBM5 
was overexpressed 
11,17,51,55
.  It would then be expected that similar results would be obtained 
with other stressors.  However, one should note that RBM5 may not increase the effects of a 
stressor at various concentrations, as high concentrations (100 μM) of cisplatin was a strong 
inducer of cell death, and did not require RBM5 expression to potentiate its effects (Figure 10).   
RBM5 enchances apoptosis through numerous apoptogenic stimuli, in many different cell lines, 
and it is, therefore, not unexpected that high RBM5 expression resulted in cisplatin-mediated 
apoptosis in GLC20 cells.   
Interestingly, RBM5 expression alone was not enough to induce cell death (Figures 9, 11 and 
12).  The lack of apoptosis in the RBM5-expressing cells that were not exposed to cisplatin 
suggests that an external stimulus is required to initiate the cell death/apoptotic process and that 
RBM5 may potentiate it.  Possible mechanisms by which RBM5 could potentiate apoptosis 
could be through the upregulation of pro-apoptotic proteins such as p53 and BAX  or increases in 
cytochrome c levels that are not high enough to initiate apoptosis, but high enough to promote 
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apoptotic signaling with stimulus.  RBM5 expression also correlates with a decrease in anti-
apoptotic Bcl-2 protein 
55
, which may increase activation of apoptosis in the presence of a 
stressor.  Lastly, another possibility is that cisplatin initiates cell death via its ability to bind to 
DNA, which initiates apoptosis through p53 or MAPK 
121,122,123,124,125
. RBM5 expression 
correlates with an increase in p53 
54
 that, on its own, may not be able to initiate apoptosis. It is 
possible that upon cisplatin binding to the DNA, the increase in p53 or the decrease in pathways 
such as KRAS, that regulate MAPK, increases the apoptotic response to cisplatin. 
Further analysis of the mechanism by which RBM5 expression influences apoptosis is required 
within the GLC20 cell model.  Studies examining the expression levels of potential RBM5 
targets such as BAX, Bcl-2 and p53 should be performed to detect any changes in expression 
levels. Additional experiments using the GLC20 sublines with other initiators of cell death would 
indicate whether or not this observed apoptosis is a cisplatin-specific event, which would aid in 
understanding how RBM5 may influence apoptosis. 
4.6 Effect of RBM5 on RBM10 alternative splicing 
The fact that the high RBM5-expressing subline, C4, had a significant increase in RBM10v2 and 
a measurable decrease in RBM10v1 proteins expression levels (Figure 13) suggests that RBM5 
may influence the exclusion of exon 4 within RBM10. Increases in RBM5 expression have been 
implicated in the exclusion of exons within various targets such as exon 4 of AID 
65
, exon 7 of c-
Flip 
61,64
, exon 9 of Caspase 2 
60
, exons 40 and 72 of  Dystrophin 
66
 and exon 6 of FasR 
61
.  
Whether RBM5 is directly or indirectly responsible for the exclusion of exon 4 (alternative 
splicing) in RBM10 was not addressed in this study.  
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The changes in RBM10v1 and v2 expression levels in the C4 subline suggest potential 
differences in the roles of each RBM10 variant in the GLC20 cell model.  A recent study using 
GLC20 cells showed that there was a two-fold increase in an isoform of RBM10v1 that lacks a 
valine, promoting increased expression of lung cancer-specific isoforms of NUMB, a component 
of the Notch pathway that regulates cell proliferation 
74
.  RBM10v1 is more highly expressed 
than v2 in many cancer cell lines, such as Jurkat cells 
72
, but has lower expression than v2 in 
non-cancerous cells such as H9C2 cardiomyocytes 
29
, C2C12 myoblasts 
142
, and bronchial 
epithelial BEAS-2B cells (unpublished).  It could then be suggested that high RBM5 expression 
influences the observed decrease in RBM10v1 expression and increase in RBM10v2 expression. 
The changes in RBM10v1 and v2 expression may also be one of many alterations that occur in 
cancer, with high RBM10v1 levels indicating a cancerous phenotype and high RBM10v2 levels 
indicating a non-cancerous phenotype. Further expression level research in different cell lines 
and tissue specimens would need to be completed to confirm these suggestions. 
4.7 RBM10 function in the GLC20 SCLC cell model 
Having observed a change in the expression of RBM10 in relation to RBM5 expression, we 
investigated RBM10 function in the GLC20 cells. Using three stable RBM10 knockdown pooled 
sublines created from non-variant specific shRNA, the decrease in cell proliferation related with 
the level of knockdown (Figure 15). These results indicate that RBM10 expression influences 
GLC20 cell proliferation.  RBM10 was previously implicated in cell proliferation through 
regulating proteins that regulate proliferation, further validating our findings 
56,85
.   
Although the shRNA used in this study was not variant specific, one could assume that the 
RBM10 knockdown resulted in decreased levels of RBM10v1, as there is much more RBM10v1 
protein than v2 (Figure 5). This result agrees with the decrease in RBM10v1 protein (Figure 13) 
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that was observed in the slow-growing (Figure 7) high RBM5-expressing C4 subline.   The 
dominant RBM10v1 isoform found in GLC20 cells promotes a lung cancer specific NUMB 
variant, which promotes cell proliferation 
74
.  Decreased cell proliferation in the RBM10v1 
knockdown sublines would then suggest a downregulation of the pathway of the lung cancer 
specific NUMB variant.  However, repeating the studies performed using variant specific shRNA 
and monitoring the expression of the specific NUMB variant would have to be completed in 
order to confirm this assumption. 
4.8 Further Directions 
A further understanding of the role of RBM5 in this SCLC model would be an ideal direction for 
future studies.  In order to understand the mechanism of cisplatin-mediated apoptosis and 
whether or not RBM5 is directly involved in cisplatin-specific pathways, studies exploring the 
apoptotic pathways activated in GLC20 cells in the presence of cisplatin and how RBM5 
influences an increase in apoptosis should be conducted. Studies observing how RBM5 
decreases GLC20 cell proliferation by cell cycle analysis or EGFR/RAS and Wnt/β-catenin 
pathway inactivation would aid in understanding the role of RBM5 in SCLC. Further analysis of 
the function of RBM5 in primary tissue samples or mouse models would aid in confirming 
assumptions proposed in this study. Using the GLC20 model to explore the effect of RBM5 on 
cell death induced by other common SCLC chemotherapies, highlighted in Table 4, would 
provide insight into whether RBM5 potentiates the cytotoxicity of multiple chemotherapy agents 
or whether RBM5 generally increases apoptosis in conjunction with any apoptogenic agent.   
To elucidate the role of RBM10 in the GLC20 model, further research understanding the 
relationship between RBM5 expression and cellular RBM10v1 and RBM10v2 levels would 
provide insight into the function of these RBM proteins and their impact on cell growth and cell 
 86 
 
death pathways.  The relationship between RBM5 and RBM10 should also be explored further, 
to understand if and how they regulate each other’s expression.  Lastly, investigations into 
RBM10v1 specific knockdown or RBM10v2 specific overexpression should be performed to 
better elucidate the function of each RBM10 variant within the GLC20 model. 
4.9 Significance 
This study’s aim was to further elucidate the role of RBM5 in cell proliferation and apoptosis 
through a SCLC model.  In demonstrating that high RBM5 expression was associated with 
decreased cell proliferation and increased apoptosis in a SCLC cell line, some insight has been 
gained as to the potential role of RBM5 and RBM10 in lung cancer.  This study also 
demonstrated the importance of RBM5 expression level in its ability to affect different cellular 
processes.   Based on the function of RBM5 presented in this study, and others, and 
understanding that the expression of RBM5 is lost or down regulated in most lung cancers, 
RBM5 expression may be a potential prognostic tool for lung cancers.  
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